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ABSTRACT
This in vitro study investigated whether Echinacea angustifolia (Ea),
E.purpurea (Ep) and the Echinacea angustifo/iaJE.purpurea Complex
(EalEp) in mother tincture (MT), potencies of 3CH, 9CH and 15CH had any
direct antifungal and/or antibacterial action against Candida a/bicans and
Streptococcus pyogenes, respectively. These organisms form part of the
normal human flora, but in immunocompromised individuals they can
initiate opportunistic cutaneous and upper respiratory tract infections,
which are seen commonly in the general practitioner's practice.
Ea and Ep were assessed for synergistic action when combined as the
EalEp Complex. The quantitative tube potency test (TPT) and the
qualitative disc diffusion test (DDT) were used to determine the product
efficacy against twenty strains of each test organism.
Results showed that none of the homoeopathic medications tested had a
direct inhibitory antifungal effect on G.a/bicans. Ea in 15CH potency
exerted significant growth reduction of S.pyogenes. Ep at 9CH and 15CH
significantly stimulated the growth of C.a/bicans. Ep and EalEp at all
potencies and Ea MT significantly stimulated the growth of S.pyogenes.
Further studies are required to determine whether the stimulatory effects of
the various potencies of the Echinacea products on the test organisms are
additive or synergistic.
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1.0 INTRODUCTION
1.1 The problem
Echinacea angustifolia and E.purpurea are used routinely in homoeopathy to
treat conditions of acute autoinfection, symptoms of blood poisoning, upper
respiratory tract infections, skin infections and generally septic conditions.
The Echinaceas are reported to boost the immune system, which aids the
body to fight off the infection, thereby hastening the recovery process
(Murphy, 1995). This can be termed an indirect mechanism of action.
Various Materia Medica and Murphy (1995) state that Echinacea angustifolia
and E.purpurea also possess antibacterial and antifungal characteristics.
By definition, these two words, antifungal and antibacterial, are stating that
Ea and Ep have the capacity to kill or inhibit the growth and replication of
fungi and bacteria (Glanze, Anderson & Anderson, 1990).
No record of direct evidence of any prior qualitative or quantitative
antimicrobial studies having been carried out on Ea and Ep has been found
in the English literature in support of these statements.
This study was designed to investigate whether homoeopathic preparations
of these two plants in mother tincture (MT) and potencies of 3CH, 9CH and
15CH have any direct, in vitro antifungal and antibacterial effects against
Candida albicans and Streptococcus pyogenes, respectively.
In addition, this study aimed to determine whether Ea and Ep Simplexes,
when combined in a complex, would be synergistic, additive or antagonistic
in vitro.
1.2 Homoeopathy
The word "homoeopathy' literally means "like suffering" and it has become
established as a system of medicinal therapeutics based on the curing of
"likes with likes".
Homoeopathy began as early as the fourth century BC with Hippocrates,
who, after observing nature closely, announced that there are in fact two
possible methods of effecting a cure, namely, via contraries and via similars
(Eizayaga, 1991).
The way of contraries (allopathy) was to become established centuries later
as orthodox medicine to be taught in contemporary medical schools.
Paracelsus (Phillip Theofrast Bombast von Hohenheim, 1493 - 1541)
became a follower of Hippocrates in the principle of similitude. In his own
right, Paracelsus came to be considered as the father of modern
experimentalism in both the sciences of chemistry and medicine. He has
also been credited with the discovery of hydrogen in the course of his
experimental work (Gaier, 1991).
Paracelsus paved the way for the man, who was to become known as the
"father of homoeopathy", namely, the German physician, Dr Samuel
Hahnemann. He graduated from the University of Erlangen as a Doctor of
Medicine in 1779.
Subsequently, Hahnemann became disenchanted with the manner in which
medicine was being practised and he drifted away from his profession.
It was while he was translating the "Materia Medica" of William Cullen, a
Scottish physician, that he came across a section dedicated to the efficacy of
using Cinchona (Peruvian bark) in the treatment of malaria.
At this point, Hahnemann fervently disagreed with Cullen's opinion about the
pharmacodynamics relating to the mechanism of action of Cinchona (Gaier;
1991). Cullen attributed its efficacy to its bitter and astringent properties,
which prompted Hahnemann to test the medicine on himself.
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After taking the equivalent of 13 g twice daily for a few days (Eizayaga,
1991) the symptoms of an intermittent fever resulted, which was similar to
the malarial fever. When he stopped taking the medicine, the symptoms
abated. He published the results of the experiment in 1796 and the aphorism
"Sirnilia, similibus curentur' ("Iet likes be cured by likes") was born. This
then was the point of origin of homoeopathy.
1.2.1 The Basic Principles Of Homoeopathy
There are five main principles governing homoeopathy:
• Treating with similars.
• Law of single remedy.
• Law of minimum dose.
• Provings on healthy persons.
• Arndt-Schulz Law.
Similars
This principle states that an illness should be treated by a substance
capable of producing similar symptoms in a healthy person to those being
suffered by the patient (Lockie & Geddes, 1995).
As previously stated, the principle of similitude has been in existence since
the fourth century Be.
In practice, it is evident that the greater the similarity between the symptom
picture of the medicine (the drug picture) and the symptom picture presented
by the patient, the higher the rate of cure as opposed to mere palliation.
Law of single remedy
This law states that there is usually only one medicine that covers the actual
state of the patient and, as such, only the most similar remedy should be
administered.
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Today, the use of a single medicine has fallen mainly into the realm of
"classical" homoeopathy.
In contrast to this, "clinical" homoeopathy utilises complex medicines in low
potencies and is effective in bringing about immediate relief in an acute
illness. Similarly, the use of a complex i~ appropriate, when the symptom
picture is such that it is extremely difficult to pinpoint the similimum. This can
occur if the patient has a long history of clinical illness, which has led to a
host of secondary complications.
The problem of finding the similimum is compounded when, as a result of
medical complications, a patient has had to take chronic medication for a
long time. In complicated cases like this, clinical homoeopathy can be
beneficial in palliating some of the patient's symptoms. Though not entirely
eliminating the chronic illness, at least, it can improve the patient's quality of
life.
Law of minimum dose
Hahnemann demonstrated that the more diluted and dynamised (succussed)
the medicine is, the greater its efficacy and penetrative action.
Furthermore, the greater the similarity between the medicine and the
symptom picture presented by the patient, the smaller the dose that is
required to effect a cure (Eizayaga, 1991).
Provings
This refers to the experimental method by which new homoeopathic
medicines are tested on healthy persons using moderate doses. The
medicines are tested individually. Any SUbsequent changes in the mental
and physical state of the individual are carefully noted. These would then
illustrate the pathogenesis of the particular medicament.
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Hahnemann's first "primitive" Materia Medica was based on testing large
doses in healthy persons. This resulted in troublesome toxic effects being
manifested in the test subiects. In addition, the symptoms produced were
common to many substances that were tested. This was why Hahnemann
began testing smaller (potentised) doses instead. His diligence resulted in
success, because he began to notice different phenomena occurring.
Instead of the violent, purely toxicological manifestations that were noted
before, symptoms were more detailed and characteristic of the specific
substance being tested. These observations were made over a period of
time, which in turn began to give a better indication of the curative powers of
the medicine (Eizayaga, 1991).
Arndt-Schulz Law
According to Hahnemann, a homoeopathic medicine, given to a sick or
healthy person, has two successive actions, which are always opposite to
one another, meanjng that the medicine will produce two distinct symptom
patterns (Hughes, 1988). The primary pattern is related to the innate effect
of the medicine: the secondary symptom pattern refers to the response of
the organism to the effect of the medicine, which is usually opposite to the
primary effect pattern (Hughes, 1988; Gaier, 1991).
This became known as the biphasic action of drugs and found application in
allopathic pharmacology where it was also noted that very strong doses of a
substance have effects opposite to those of a very weak dose.
Years later, Professor Hugo Schulz and Dr Arndt (both orthodox medical
men in Germany) developed the Arndt-Schulz Law based on this theory.
The law is formulated as follows: -
'Minute stimuli encourage life activity, medium stimuli tend to impede life
activity and very strong stimuli tend to stop or destroy life activity.'
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This reversal of biological effect noted in various ranges of concentrations of
the same medicinal agent, is called "hormesis" (Gaier, 1991).
Professor of Biochemistry, Jacques Benveniste, and Professor Henri
Pacheco were later able to demonstrate successfully Hahnemann's theory of
biphasic drug action at the National Institute of Applied Sciences in Lyon,
France.
They conducted double-blind studies to determine the action of Gelsemium
sempervirens upon the capturing of norepinephrine, dopamine and serotonin
by synaptosomal preparations of rats' brains. Gelsemium is routinely used
in homoeopathy to treat conditions of anxiety and distress.
It was observed that in a 10.2 (1CH) deconcentration of Gelsemium, the re-
uptake of norepinephrine, dopamine and serotonin was strongly inhibited in
all fractions of rats' brains.
However, as the potencies moved higher, from 10.7 to 10-8, the inhibitory
effect was replaced by a significant re-uptake of the three medications.
1.3 Homoeopathic medicines
1.3.1 Origin
Homoeopathic medicines are to be found in the plant, animal and mineral
kingdoms. These medicines are available in the form of granules, pillules,
globules, powders, tablets, syrups, liquids, injectables, creams and drinking
ampoules.
1.3.2 Potentisation and succussion
The actual preparation of the medicine depends on whether the raw
substance is soluble or insoluble (Gaier, 1991; Eizayaga, 1991).
Two scales are generally used in the manufacturing of homoeopathic
medicines, namely, the Decimal Scale and the Centesimal Scale (Vithoulkas,
1993; Eizayaga, 1991; Gaier, 1991).
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1.3.2.1 Decimal Scale
This scale was introduced by Constantine Hering and is based on the
principle that the first potency is made by transferring one part of the
hornoeopathlc base medicine to nine parts of solvent. It is succussed ten
times. From this, one part of the succussed solution is transferred to nine
parts of fresh solvent and succussed. This process is repeated sequentially
until the desired degree of deconcentration has been achieved.
The unit of deconcentration is the decimal potency and it is denoted by a "D'
(or DH - Decimal Hahnemanian) or an "X". Thus, a 1D or 1X notation is
equivalent to a 10.1 dilution (Eizayaga, 1991).
1.3.2.2 Centesimal Scale
In contrast to the Decimal Scale, Hahnemann developed the Centesimal
Hahnemanian (CH) or (C) scale. The process of potentizing is identical to ,
what has already been described above, the only difference being that 1 part
of the base medicine is transferred to 99 parts of the solvent. This is
repeated until the desired degree of deconcentration has been achieved.
Here, a 1C or 1CH notation is equivalent to a 10 ·2 dilution (Vithoulkas, 1993;
Eizayaga, 1991).
For soluble substances, the raw plant or animal material is first macerated,
and then diluted in 90 % alcohol. This resultant liquid is then filtered and the
filtrate is referred to as the mother tincture (MT). At this point the potentizing
process can begin.
Insoluble substances are first ground to a fine powder in lactose, until
amalgamation results. This is called "trfturation".
Once the substance has been triturated to 3CH, it can be taken through to
solution and potentized in the usual way (Jouanny, 1994).
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Differentiating between low, medium and high potencies can be a cause for
controversy, depending on whether one is of the classical or more clinical
school of thought. Jouanny (1994) provides a guideline that has proven
useful in general practice. Any potency below 5CH can be regarded a low;
7CH and 9CH are medium and any potency at or above 15CH is high.
1.4 The theory behind succussion
When one considers the manner in which homoeopathic medicines have
been prepared, it seems hard to imagine that any potencies beyond 12CH I
24DH could have any therapeutic efficacy at all, because, according to
Avogadro's Principle, not a single molecule of the original substance should
be present in the solvent.
Avogadro's Principle is one of the cornerstones on which modern chemistry
is based and states that no molecule of the original substance will remain in
the solvent when any substance is diluted beyond 6.0225 x 10 0 23• In
homoeopathy, the 12CH /24DH potency has been deconcentrated beyond
Avogadro's number.
The question is - do homoeopathic potencies of 12CH and beyond have any
therapeutic efficacy at all?
In an attempt to solve this mystery, a long series of chemical, physical and
biological experiments have been undertaken. These have yielded
repeatable results that are of statistical significance (Gaier, 1991).
These results indicate the existence of a force field within the potencies that
is of a physico-chemical nature. This force field is transferred forward into
the ultramolecular deconcentration stages during the potentization and
succussion process. The question is, how?
In 1994, Heintz, using infrared spectrophotometry, demonstrated that the
succussion process produced polymers in the solvent. Furthermore, a
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clustering effect was being transferred and amplified with each successive
potency. The mechanical force of the succussion causes the medicinal
substance and solvent to become rearranged into giant polymers (macro-
molecules). This rearrangement is unique for each base substance used
(Gaier, 1991).
Each polymer maintains a constant 3-dimensional (spatial) arrangement,
referred to as a solvation structure (Gaier, 1991).
The actual physics behind the formation of these solvation structures is
explained as follows: it is known that a large number of crystallisation
patterns appear in ice under different barometric pressures (Gaier, 1991).
Hence, under non-freezing temperatures, such as those at which
potentization takes place, the potential exists for a variety of polymerisation
patterns to be formed should the conditions become favourable.
The succussion process creates the following favourable conditions:
• Water molecules split, which releases ions for inclusion as constituents .
of replicating polymers.
• Within the solvent, air and other gases are dissolved. These are
compressed during succussion, which, in turn, results in an abrupt
temperature increase around those few split water molecules (Gaier,
1991). This heat will then induce sporadic disintegration of the
molecules, resulting in the liberation of more ions, which can then be
incorporated into new polymers, which, in turn, are moulded into solute
specific shapes. Further succussion strokes will continue to fracture
them, thereby allowing this mechanism to continue throughout the
deconcentration series.
It is again emphasised that these polymers have shapes specific to each
homoeopathic base substance used. Earlier researchers had shown that
polymer replication continues even in the absence of the original solute, i.e.,
beyond the 12CH potency (Gaier, 1991).
The polymers are stable and are only destroyed b.y heat, ultrasound or
certain types of irradiation. In the Department of Pharmacy at Montpellier
University, Dr Luu-D-Vinh proved this. She used a Ramon laser to
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demonstrate the polymerisation replication sequence brought about by
succussion in potencies ranging from 1CH to 30CH and beyond (Eizayaga,
1991; Gaier, 1991).
1.5 The "placebo" effect in homoeopathy
Homoeopathy has continued to be controversial from the time of its inception
in 1796 to today. Many sceptics maintain that the chief mechanism of action
of homoeopathic medicines is purely psychosomatic and hence, they
basically act as a placebo. A placebo, by definition, is a
pharmacodynamically inert or inactive substance.
Research conducted over the last 70 years has brought interesting results to
light, which, at the very least, should pose the question whether it is accurate
to assume that homoeopathic medicines are inert. The following examples
illustrate the point.
• In 1927, Konig bred frog larvae (Rana Fusca) from fertilised egg to .
embryo to young tadpole in lead and silver nitrate in potencies from 10-1
to 10.30• There was a significantly higher death rate among the larvae
exposed to the potencies than in the unexposed, control group.
• In 1930 the effect of various potencies of mercuric chloride on the rate of
starch fermentation by salivary amylase was studied. The effect of other
potentised substances on the fibrinolytic activity of pepsin and trypsin
was also investigated. These studies were controlled and it was found
that all potencies, up to 10-12°,had an effect in both fermentation and
fibrinolytic studies (Gaier, 1991).
• In 1988, Benveniste of the South Paris University, found basophils
responded to a solution of antibodies potentised serially all the way
through to 10 -120. The degranulation response was inhibited at lower
potencies, but stimulated at higher potencies (Gaier, 1991).
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• In 1931, Boyd and Paterson demonstrated the Schick test for diphtheria
could be changed from positive to negative through the oral
administration of either diphtherinum 10 -402 or alum precipitated toxoid at
10 -60. The results of the change from Schick-positive to Schick-negative
were more than 12 times the accepted rate of spontaneous change
(Gaier, 1991; Sankaran, 1996).
• In 1965, Cier demonstrated the influence of prior treatment with alloxone
10.9 on the subsequent diabetogenic action of crude alloxone on mice
(Eizayaga, 1991; Gaier, 1991). Intravenous injections of alloxone (30 -
60 mg/kg) resulted in hyperglycaemia in mice. However, those mice,
which were first given 6 daily injections of alloxone 9CH, did not develop
hyperglycaemia when injected with crude alloxone at 30 - 60 mg/kg:
This "protection" conferred by alloxone 9CH was verified histologically.
The pancreas of control mice exhibited degeneration of the B-cells of the
Islets of Langerhans. This was not evident in those mice, which were
given the alloxone 9CH.
• Popp, a biophysicist, (1988) further challenged the orthodox view of the
placebo effect by conducting research on the effects of high and low
homoeopathic potencies on mast cells, Iysosomes and zinc-dependent
enzymes. His studies revealed that mast cells increased histamine
release when exposed to zincum metallium in 40H and 60H and
phosphorus as high as 300H.
• Lysosomes showed an increase in glycosidase and protease activity
under the influence of ferrum phosphoricum in 80H potency. Popp
further demonstrated that, under the influence 'of certain other
homoeopathic medicines, mitochondrial respiration could be intensified
and xanthine oxidase and microsomal NAOPH~cytochrome-P45 reductase
could be activated.
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These pioneering studies prove that homoeopathic medicines are not inert.
Furthermore , it is evident that biochemical investigative methods are well
suited to demonstrating the effects of homoeopathic medicines on cellular
metabolism. Classical chemical methods , unfortunately, have not proved
very useful , because their sensitivity is rather limited (Sankaran, 1996).
Experimental work of this nature has furthered scientific knowledge about
the details of the mechanism of the physiological response induced by
homoeopathic medicines. It may as yet not be able to answer the "why is?"
or "how is?" questions, but it certainly has answered some of the "what
happens?" questions in homoeopathy.
1.6 Echinacea species
This plant genus belongs to the Family Compositae.
The Echinaceas, or coneflowers derive their name from the Greek word for
'hedgehog' from the spiky appearance of the seed case and possibly that of
the central disc of the flowers (Fig. 1.1).
Figure 1.1 Echinacea species growing in the field
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1.6.1 Echinacea angustifolia [Esanguinea]
Echinacea angustifolia, like its close relative Epurpurea, (which is described
more fully in the next section for comparison) occurs naturally throughout the
North American prairies and plains.
Echinacea angustifolia is a tap-rooted perennial with lance-shaped leaves
and it flowers before Epurpurea. Another difference is that, while the rays of
Epurpurea are purple to white in colour, the rays of Eangustifolia are a
deep purple (Foster, Duke, 1990) (Fig. 1.3).
Phytochemically, Eangustifolia is differentiated from Epurpurea by its
relatively high content of epishiobunol, beta-farnesene and an unidentified
compound, Compound X (Schulthess, Giger, Baumann, 1991).
Furthermore, only Eangustifolia has echinacoside (triglycoside caffeic acid-
Fig. 1.2) found specifically in the root. This compound is said to have
antimicrobial and antihepatotoxic activity (Harborne, Baxter, Moss, 1997).
However, Foster (1991) states that Epallida also contains echinacoside
following the 1988 studies of Bauer, Khan and Wagner...
. .,: ..
" HO
HO
Figure 1.2 Structure of echinacoside
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Figure 1.3
Diagrammatic representation of the morphology of Echinacea angustifolia
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Eangustifolia does not have the astringent taste and anaesthetising effect of
Epurpurea; rather it has a soapy taste.
In regard to clinical application, Eangustifolia has a similar mechanism of
action as Epurpurea (Grieve, Leyel, 1980).
Hence, Eangustifolia is also attributed with antimicrobial, anti-inflammatory,
anti-catarrhal and immunostimulatory properties.
1.6.2 Echinacea purpurea [purple coneflower]
Echinacea purpurea is the most common of the Echinaceas, or coneflowers
and it is also the species most frequently used in medicinal preparations.
More research has been carried out on this species than on any of the other
Echinacea species.
It is distinguished from other Purple Cone flowers by its oval, coarsely
toothed leaves and orange-tipped bristles on the flower heads (Foster &
Duke, 1990) (Fig. 1.4).
It flowers between June and September and is found in open woods, thickets
and cultivated gardens on rich, sandy, therefore mostly dry ground.
Echinacea purpurea has a fibrous, adventitious root system in contrast to the
tap root system of E.angustifolia.
E.purpurea has a slight aromatic, sweetish taste at first, which then leaves a
bitter aftertaste (Foster, Duke, 1990; Grieve, Leyel, 1980).
A further point of interest is that it is possible to differentiate between the
achenes (fruits) of the various Echinacea species, not only structurally, but
phytochemically as well.
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Figure 1.4
Diagrammatic representation of the morphology of Echinacea purpurea
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The achene of Echinacea contains one seed that is surrounded by a solid,
essential oil-containing fruit wall. This provides both a mechanical and
chemical defence for the embryo (Schulthess, Giger, Baumann, 1991).
While germinating, the developing seedling sheds its fruit wall and starts
synthesising a variety of phytochemicals directed against predators and
pathogens in the soil.
For the purpose of phytochemical differentiation, E.purpurea is characterised
by a relatively high content of carvomenthene, caryophyllene and
germacrene D (Table 1.1, adapted from Schulthess, Giger, Baumann, 1991).
Furthermore, only the achene of E.purpurea contains trideca-2E, 7Z-diene-
10, 12-diynoic acid isobutylamide (Bauer, Remiger et a/:, - cited in
Schulthess, Giger, Baumann, 1991).
Table 1.1 - Major compounds (GC analysis) in the ethanolic extract of the·
achene of Echinacea species
Compound E.angustifolia E.purpurea
a. - pinene 16.7 % (8.4:28.0) 5.7 % (2.5:11.1)
13 - pinene 19.5 (11.2:23.9) 7.8 (3.6:20.8)
myrcene 3.6 (1.3:11.1) 6.8 (1.3:16.4)
carvomenthene 2.6 (0.0: 6.4) 16.4 (5.5:27.8)
caryophyllene t 4.6 (1.4: 7.3)
13 - farnesene 4.8 (1.5: 8.9) t
germacrene D t 11.1 (3.8:26.5)
germacrene D deriv. t t
epishiobunol 3.5 (2.2: 5.8) t
compound X 5.8 (4.4: 8.7) t
1,8 - pentadecadiene t t
% of total compounds 59.6 % 55.6 %
by GC analysis
t =trace
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Other compounds that are found in the Echinaceas in general, are inulin,
betaine, resins, fatty acids and two isomers of 2-methyltetradecadiene
(Budavert, O'Neil, Smith, 1989). The proportions of all these compounds are
variable, dependingon the nature of the plant harvest (Roesler, Steinrnaller,
Emmendorffer, et a/., 1991a).
The NorthAmerican Indiansare said to have used Echinacea for more
medicinal purposes than any other plant group. Indeed, the root was used
for treating anything from snake and spiderbites, to cancers, toothache,
burns, wounds and respiratory tract infections (Foster, Duke, 1990).
Today, as a result of clinical observations, Echinacea has achieved
worldwide acclaim for its antifungal, antiviral, antibacterial, antiallergenic and
anti-inflammatory properties (Ody, 1993). All the homoeopathic Materia
Medicas state that Echinacea has clinical application in the treatment of
upper respiratory tract infectionssuch as tonsillitis and pharyngitisand
cutaneous infections involving the formation of pustules, boils, carbuncles,
impetigoand abscesses.
With regard to the antimicrobial effects of Echinacea specifically the
polyacetylenes, which are found in the plant, are reported to have
bactericidal and fungicidal activity (Bauer, Khan - cited in Schulthess, Giger,
Baumann, 1991).
In addition, antiviral properties of E.purpurea have been demonstrated using
in vitro cell cultures of the Herpes and Influenza viruses. Bothof these
viruses were inhibited by E.purpurea extracts (Bauer, Wagner, 1996).
However, Harnischfegerand Stolze (1980) state that, rather than being
virucidal as such, Echinacea prevents initial viral penetration into the host
cell by helping to maintain the integrity of the host cell membrane.
The immunostimulatory properties of Echinacea have been attributed to the
methylbutamides of C11 and C16 alkenes and alkynes that have been isolated
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from the plant (Bauer, Remiger - cited in Schulthess, Giger, Baumann,
1991).
Luettig (1989) states that the polysaccharide fractions of E.purpurea
stimulate macrophages to secrete tumour necrosis factor-alpha (TNF-a),
Interleukin-1 (IL-1) and -6 (IL-6). This is yet another example of the
immunostimulatory action of E.purpurea. TNF-a, IL-1 and IL-6 are natural,
immune response proteins.
TNF-a specifically possesses anti-cancer properties and is also produced in
response to bacterial toxins (Glanze, Anderson & Anderson, 1990).
Similarly, Roesler and co-workers (1991b) stated that these polysaccharide
fractions of E.purpurea enhance phagocytosis and microbiocidal activities of
macrophages, both in vivo and in vitro. It was also found that injection of the
purified polysaccharide of E.purpurea into mice, mediated protection against
systemic infections with Listeria monocytogenes and Candida albicans, This
protection appeared to be conferred due to enhanced migration of
polymorphonuclear (PMN) cells into the peripheral blood.
Based on these findinqs, these workers stated that a clinical protocol for the
treatment of chronic Candida infections with E.purpurea had been
scheduled.
In this same study, it was noted that, through the action of these
polysaccharides, the KOpffercells of the liver of the mice demonstrated
greater inhibitory effects on the growth of G.albicans.
All the literature is in agreement that the Echinacea species have an
immunostimulatory action. Burger, Torres et al., (1997) maintain that the
activation of the cytokine pathways is an integral part of the
immunostimulatory activity of Echinacea, although the exact mechanism by
which this occurs is still unknown.
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In support of this, they had observed that concentrations of Epurpurea as
low as a 0.025 Ilg/mt effectively induced cytokine production by human
peripheral blood macrophages in vitro.
Echinacea species also contain echinacin. This compound had been used
experimentally as a hyaluronidase antagonist (Koch, Hasse, 1952; Busing,
1955 - cited in the Merck Index, 1989).
Hyaluronidase is an enzyme that hydrolyses hyaluronic acid, which is the
connective tissue ground substance found in intercellular spaces. Certain
organisms use this enzyme as a spreading factor, to allow them to migrate
through the tissue substance. This is discussed in greater depth under the
pathogenesis of S.pyogenes.
1.6.3 Echinacea purpurealEangustifolia Complex
Echinacea has become the top-selling herbal product in the United States of
America for the past four years and is widely used in the United States and
Europe for the treatment of URTls (Melchart, Walther, Linde et al., 1999).
The authors did not specify the Echinacea species used in the marketed
products.
In addition to URTls and any immunosuppressive or septicaemic conditions,
it has found application in the treatment of cutaneous disorders such as
boils, carbuncles, impetigo and erysipelas (Grieve, Leyel,1980; Murphy,
1995).
Two microorganisms, C.albicans and S.pyogenes can be initiators of both
cutaneous infections and URTls.
Though the extracts obtained from Epurpurea and Eangustifolia can be
used separately for treatment purposes, research has shown that, when
used in combination, they act synergistically, thus enhancing their efficacy
(McKenna, 1996).
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Similarly, Harnischfeger, Stolze (1980 ) stated that the tota l extract (mother
tincture) of Echinacea always exhibits a greater effect than any isolated
constituent of the extract.
1.7 Candida albicans
1.7.1 Morphology
Candida albicans is a Gram-pos itive , unicellular, oval , budd ing yeast that
produces pseudomycel ium, both in culture and in tissues and exudates .
In Gram-stained smears of exudates, this organ ism measures 2-3 11m x 4-6
urn (Jawetz, Melnick, eta!., 1987) (Fig.1 .5).
On Sabouraud's dextrose agar (SDA), soft cream-coloured colon ies deve lop,
which have a characteristic yeasty odour. C.albicans ferments glucose and
maltose, forming both acid and gas; produces acid from sucrose and does
not attack lactose. Tak ing note of these biochemical characteristics is very
important, as it aids in identifying and differentiating between the various
spec ies of Candida in the laboratory.
Figure 1.5 Gram-stain ed smear of C.albicans
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This organism grows opt imally at 37 °C, and between pH2 and pH3. It is of
diagnostic significance that , of all the species of Candida, only young
cultures of C.albicans and C.stellatoidea will form germ tubes with in 2 - 3
hours when incubated in serum or albumin at 37 °C. This gives a
presumptive identification of the organisms, wh ich could be of therapeutic
significance.
1.7.2 Carriage
C.albicans forms part of the normal flora of the buccal cavity, large intestine
and genito-urinary tract in heal thy indiv iduals (Freeman, 1979).
Vag inal carriage varies between 5 - 30 %. The use of oral contraceptives is
often associated with higher levels of carriage (Rippon, 1982).
Braude (1983) sta tes oral carriage is about 10 %, intestinal/rectal carr iage is
approximately 15 % and vaginal ca rr iage is about 10 %. However, these
levels can elevate to 40 % in elderly pat ients , or in those on antibiot ics.
Evans & Gentles (1985) cons ider the ora l freq uency of C.albicans carriage in
healthy individuals is about 2-3 %, but in hospitals this can rise to 13-76 %.
Approximately 40 % of the population carry C.albicans and it can act as an
opportunistic pathogen in debilitated individuals. Th is means that it can
begin to initiate an infective process should an individual become
immunocompromised for any reason.
Examples of immunosuppression where this has occurred are HIV infection ,
renal dialysis, recent surgery, cancer, cort icostero id therapy, and excessi ve
use of antibiotics, intravenous narcotics abuse, indwelling urinary or
intravenous catheters and in the extremes of age .
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1.7.3 Pathogen esis
Candida albi cans causes between 80 -90 % if infections, but oth er Candida
species can be more common at certain cutaneous or mucocut aneous sites,
for example, C.parapsilosis in fing ern a ils and C.glabrata (Torulop sis
glabrata) causes approximately the same number of infections in the vagina
as C.albicans (Evans & Gentles , 1985; Dr C.N . Young, per sonal
communication).
In order for C.albicans to initiate infection, it f irst has to adhere to the tissue
surface (Hay - cited in Noble, 1993). The outermost layer of the or ganism is
composed of mannoprotein and th is is said to be responsible fo r the
adhesion process. Bacterial flo ra can also inf luence adhesion , by competing
with Candida for receptor sites or, alternatively, by secreting metabol ites
which have fungistatic activity.
Candida can ex ist in yeast or in f ilamentous form. The latter has greater
adherence capabil it ies. This is attributed to the increased surface area of
this state.
Furthermore, enzymes, endotoxins an d other metabolites further enhance
pathogenesis, as it has been noted that proteinase-def icient strains of
C.albicans are less viru lent than prote inase-producing strains (Boyd, 1988).
An interesting observat ion made during virulence stud ies , is that C.albicans
has a predi lecti on fo r pat ients on g luco-corticoid therapy (Boyd, 1988). Th is
is associated w ith the fact that C.albicans possesses a pro te in that has a
high affinity for vertebrate corticosteroids. Th is raises the possibility that
steroid hormones affect yeast behaviour.
The process of adhesion is a time-dependent process that is affected by
factors such as temperature, pH and the presence of certain drugs.
However, adhesion can also be inhibi ted by certai n sugars such as
mannose.
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Candida also has a complement (C3d ) receptor on its surface, which
contributes to its pathogenesis (Noble, 1993). Although a matching
receptor site on the host has not been identified yet, it is thought that blood
group substances expressed on epithelial cells are possible candidates (Hay
- cited in Noble, 1993).
Once adhesion and initial infection has begun, there is an influx of
neutrophils into the infected epithe lium, accompanied by hyperkeratosis and
parakeratosis. Lymphocytes and plasma cells then infiltrate into the upper
dermal layers and so the infection progresses (Noble, 1993) .
In some chronic infections of the oral mucosa, the epitheli um atrophies,
resulting in dysplastic changes within the basal layers of cells . If these
dysplastic changes are severe enough, it could develop into oral cancer in
certa in patients, especially if the person is also a smoker (Hay - cited in
Noble, 1993).
1.8 Streptococcus pyogenes
The bacteria belonging to this family are Gram-positive , spherical to ovoid,
non-motile cocci, less than 2 urn in diameter . They occur in pairs , chains or
tetrads when grown in liquid media and they are facultative anaerobes,
which means they flourish in an anaerobic environment, although they are
able to grow under aerobic conditions.
1.8.1 Morphology
Streptococcus pyogenes belongs to the family of Streptococcaceae (Holt et
al., 1977). This bacte rium does not require a high CO2 tension for rapid
growth and forms tiny colonies surrounded by an area of complete
haemolysis (f3-haemolysis) on blood agar (BA) (Fig. 1. 6) .
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According to Noble (1993), the umbilical stumps of neonates are an
important source of recurrent infections in nurseries; for though the stumps
may appear healthy, they often harbour S.pyogenes.
For the most part, human infections with pyogenic streptococci result from
autoinoculation or by direct transmission via airborne droplets. There are
also instances where infection can spread via pets carrying Spyogenes
(Barnham - cited in Noble, 1993).
Throat strains of Spyogenes can readily be cultivated from contaminated
clothing, bedding and other fomites. However, the bacterium does not retain
its infectivity indefinitely once away from the human host.
Like Candida, this coccus forms part of the normal flora in humans, but the
moment debility or immunosuppression arises within the host, S.pyogenes
can begin to initiate disease processes.
1.8.3 Pathogenesis
There are several factors that contribute to the virulence of the beta-
haemolytic streptococci. The M-protein molecule, located on the cell
envelope, is considered to be a major virulence factor. This molecule is
double-stranded and coiled; it possesses an affinity for binding to fibrinogen,
fibronectin and beta-2-microglobulin. It is precisely this characteristic that
plays a crucial role in the attachment of the bacterium to wounds and clots in
the first stage of colonisation and infection. The bacterium can also attach
to any foreign bodies within a wound should it become coated with host
proteins (Barnham - cited in Noble, 1993).
M-protein also interferes with complement deposition and confers resistance
to phagocytosis. It has been noted that the higher the quantity of M-protein
on the coccus, the greater is its virulence.
Furthermore, it has been observed that immunological cross-reactivities take
place between the M-protein and the protein components in mammalian
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heart, brain, kidney and joint tissue, which may trigger and auto-immune type
sequela.
Other projecting cell-surface molecules, similar in structure to M-protein,
have been shown to initiate the destruction of complement CSa.
Complement CSa is an important signal substance in the attraction of
leukocytes via chemotaxis and in binding to IgG and IgA antibodies.
Immunoglobulin binding properties have been found in a high proportion of
clinical isolates of S.pyogenes, for example, IgG-binding activity is common
in pyodermic isolates. However, the exact role that this plays in
pathogenesis remains unclear (Barnham - cited in Noble, 1993).
Complement per se is one of 11 complex, enzymatic serum proteins that
participate in various physiological reactions, including anaphylaxis and
phagocytosis (Glanze, Anderson, Anderson, 1990).
There are other components of streptococci that enhance virulence.
• Streptokinase (fibrinolysin) converts human plasminogen to plasmin,
which then causes lysis of fibrin clots (Jawetz, Melnick, et al., 1987).
• Streptodornase is an enzyme that depolymerises DNA.
• Hyaluronidase splits hyaluronic acid, which is an important component
of connective tissue ground substance. This enzyme thus aids in the
spreading of the infecting organism through the tissues.
• Erythrogenic toxin is responsible for the scarlet fever rash. Only those
strains of streptococci liberating this toxin will cause scarlet fever.
• Diphosphopyridine nucleotidase, an enzyme, is thought to be related
to the ability of the coccus to kill leukocytes.
• Haemolysins are enzymes involved in ~-haemolysis, when erythrocytes
are completely disrupted, resulting in the release of haemoglobin. These
haemolysins are referred to as Streptolysin 0 and Streptolysin S. The
former is a protein that becomes haemolytically active in the reduced
state, i.e. when it acquires electrons. When oxidised, it becomes inactive
again (Jawetz, Melnick et ei.. 1987). It is also said to damage the
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integrity of cholesterol-containing membranes, thereby causing the
release of cytoplasmic constituents. This is then thought to be disruptive
to phagocytosis and inhibitory to chemotaxis (Barnham - cited in Noble,
1993).
Streptolysin S is the agent responsible for the zones of haemolysis that are
evident on blood agar.
It is interesting to note that some species of Streptococcus exhibit Q-
haemolysis where there is only partial lysis of erythrocytes. The result of
this is the formation of a green pigment that can be seen surrounding the
colonies on blood agar (Jawetz, Melnick et aI., 1987).
Various streptococcal enzymes are also thought to assist in the liquefaction
of pus, which further assists in the spreading of the organism into the tissues
and lymphatic channels. Should the organism gain entry into the
bloodstream, a bacteraemia will supervene.
• Fimbriae (pili): the presence of these structures in S.pyogenes
contribute to the ability of the bacterium to attach to epithelial cells
(McBride - cited in Noble, 1993).
• Other mechanisms - preliminary evidence suggests that haemolytic
streptococci can stimulate macro phages to produce tumour necrosis
factor (TNF), which plays a pivotal role in the development of toxic shock
syndrome (Barnham - cited in Noble, 1993).
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2.0 INFECTIONS CAUSED BY C.ALBICANS AND S.PYOGENES
Introduction
Though so different, C.albicans and S.pyogenes share a commonality in two
respects. Both form part of the normal human flora and, should conditions
become favourable, both of these organisms can initiate upper respiratory
tract and cutaneous infections.
2.1 Upper respiratory tract infections
2.1.1 Candidosis
Candidosis is one of the most frequently encountered fungal diseases known
to man (Beeson & McDermott, 1963). Under ordinary circumstances, in vivo,
the growth of the causative yeast is held in check by the body's defence
mechanisms and other members of the normal microbial flora (Freeman,
1979).
The scenario changes when an immunocompromised state is initiated within
the body, because Candida begins to proliferate at a rapid rate, thereby
establishing an infection.
Oral candidosis, often referred to as "thrush", is a common occurrence in
babies, among denture wearers, the aged, in states of debility, obesity,
diabetes mellitus, anaemia, intravenous drug abuse, indwelling urinary or
intravenous catheters, recent surgery, chemotherapy or corticosteroid
therapy. It is also often seen prior to other manifestations of HIV disease.
Hippocrates was one of the first observers to describe "aphthae" or "thrush"
in debilitated patients as early as 460 - 377 BC (Rippon, 1982).
Oral aphthosis due to Candida I infections usually results in glossodynia
(pain in the tongue), dysphagia (difficulty in swallowing) and halitosis. This
condition presents with creamy-white patches overlying an erythematous
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mucosal base (Greenwood, Slack, et aI., 1992). These patches can
coalesce to form a pseudomembrane that covers the tongue, soft palate or
other oral surfaces. The pseudomembrane is composed of spherical yeast
cells (usually C.albicans), pseudomycelium and cellular debris (Boyd, 1988).
There are instances when this membrane can become so large that it
obstructs breathing. If untreated, this condition can spread from the mouth
and throat distally to the oesophagus, where it can initiate candidal
oesophagitis.
In some cases the white plaques are not so obvious and, instead, the oral
mucosa appears glazed and atrophic.
The angles of the mouth may be cracked and inflamed (angular
cheilitis). Some patients present with median rhomboid glossitis. This
refers to a lozenge-shaped area of infection on the dorsal surface of the
tongue (Hay - cited in Noble, 1993).
Patients with HIV infection or AIDS tend to develop a particularly tenacious
form of oral candidosis, which may co-exist with Herpes simplex. In this
group, oesophageal involvement is a problem (Hay - cited in Noble, 1993).
This organism can also infect the gastrointestinal tract (GIT) or invade the
blood stream to produce a fungaemia thus resulting in generalised lesions
(Goudie, et aI., - cited in Anderson, 1976).
2.1.2 Streptococcosis
Sore throat is one of the commonest ailments seen by family doctors.
Pharyngitis is usually viral, but may also be caused by Group A, f3-
haemolytic streptococci and differentiating between them can be difficult.
Bacterial pharyngitis and acute tonsillitis are caused almost exclusively by
Streptococcus pyogenes.
Primary pharyngeal infection with the Group A, beta-haemolytic streptococci
is characterised by fever, sore throat, beefy pharynx and a purulent
pharyngo-tonsillar exudate with a leukocytosis. Concommitant cervical and
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submaxillary lymphadenopathies are common (Anderson, Scotti, 1968;
Berkow, Fletcher, et aI., 1987). Perianal cellulitis is commonly seen in
children with a streptococcal URTI (Barnham - cited in Noble, 1993).
The extremes of streptococcal infection only occur in about 20 % of patients
with Group A, l3-haemolytic streptococci in the throat; the other 80 % are
asymptomatic or only have a mild sore throat. However, should a
streptococcal sore throat be inadequately treated, complications can arise
when the infection penetrates into the tonsillar capsule, resulting in
peritonsillar cellulitis with abscess formation, "quinsy" (Anderson, Scotti,
1968). There is severe pain when swallowing and the patient is febrile and
tends to tilt the head towards the side of the abscess. The muscles of the
jaw also tend to go into spasm (trismus). On examination, the tonsil is
displaced medially by the peritonsillar cellulitis and abscess (Berkow,
Fletcher, et aI., 1987). The soft palate is erythematous and swollen; the
oedematous uvula is also displaced to the opposite side.
Tonsillitis is an acute infection of the palatine tonsils due to viral or
streptococcal infection. The symptoms include sore throat, fever, malaise,
headache and vomiting. Tonsils are oedematous and hyperaemic. A
purulent exudate and a thin, white, non-confluent membrane may be evident
on the tonsils. A distinguishing feature is that this membrane peels away
easily from the tonsil, without bleeding (unlike the pseudomembrane of
Corynebacterium diph theriae ), (Berkow, Fletcher, et aI., 1987).
Parapharyngeal abscess occurs as a consequence of pharyngitis or
tonsillitis and can occur at any age. There is suppuration of a pharyngeal
lymph node with consequent abscess formation. Unlike, candidal infections,
Group A, ~-haemolytic streptococcal disease can result in many and
prolonged complications.
Post-streptococcal diseases (sequelae) usually begin within 1 to 4 weeks
following a streptococcal infection. This latent period suggests that these
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post-streptococcal diseases are not directly due to the dissemination of the
bacteria, but are due to a hypersensitivity response to the damage done to
specific organs by the organism or its metabolites.
Streptococcal infections of the upper respiratory tract do not usually involve
the lungs. Pneumonia due to r3-haemolytic streptococci is commonly a
sequel to viral infections (Jawetz, Melnick, et aI., 1987).
• Scarlet fever is most commonly associated with S.pyogenes infection of
the throat, but it may follow infection at other sites like the skin or genital
tract (Barnham - cited in Noble, 1993). This disease is due to the
erythrogenic toxin that is produced by some Group A, r3-haemolytic
streptococcal strains. This toxin leads to a diffuse, pink-red, cutaneous
flush that blanches on pressure. Scarlet fever resembles a streptococcal
pharyngitis, but can be distinguished from it by an erythematous rash that
is best seen on the abdomen, lateral chest and cutaneous folds (Berkow,
Fletcher, et aI., 1987). Further characteristic manifestations include
circumoral pallor with a flushed face, "strawberry tongue" due to inflamed
papillae protruding through a bright red coating and Pastia's lines - dark
red lines in the creases of skin folds, (Berkow, Fletcher, et a/., 1987).
• Rheumatic fever (RF) is one of the most serious sequelae of a 11-
haemolytic streptococcal infection that could easily have taken the form
of an undetected (subclinical) throat infection, which occurred 1 to 4
weeks previously (Jawetz, Melnick, et et., 1987). In countries like
Portugal, Romania and Bulgaria, it still ranks as a major cause of death in
young adults. The actual mechanism of this disease is due to the
bacterial surface antigens forming cross-linkages with the sarcolemma
(cell membrane of the heart muscle fibres) of a patient's heart. Typical
symptoms include high fever, malaise, polyarthritis and carditis.
Eventually, the cardiac valves become damaged. Rheumatic fever has a
marked tendency to become reactivated by recurrent streptococcal
infections. With each subsequent bout of rheumatic fever, the heart
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muscle becomes more damaged. Heart valves damaged by RF may
subsequently be candidates for the development of sub-acute bacterial
endocarditis.
• Acute Bacterial Endocarditis (ABE) occurs in the course of a
bacteraemia. Blood-borne streptococci can settle on normal or
previously damaged heart valves, producing an acute, ulcerative
endocarditis. Rapid destruction of the valves can prove fatal in days or
weeks.
• Sub-acute Bacterial Endocarditis (SBE) is most frequently due to
members of the normal flora of the respiratory and intestinal tract that
have accidentally reached the blood stream (Jawtez, Melnick, et aI.,
1987). Symptoms include fever, heart murmurs, embolic phenomena,
splenomegaly and renal lesions.
Further complications of streptococcal infections will be discussed under
cutaneous infections.
2.2 Cutaneous infections
2.2.1 Candidosis
Candidosis can be divided into superficial and deep patterns of infection.
Superficial candidal infections are common throughout the world and
C.albicans accounts for 80 - 90 % of cases (Greenwood, Slack, et aI., 1992).
Infections of the skin surface tend to be confined to the moist body-fold
areas.
Candida intertrigo occurs in the groin, submammary folds, interdigital and
toe clefts, axillae and perineum. There are rare instances where infants
present with a generalised cutaneous form of candidosis shortly after birth.
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Like candidal vaginitis, it appears as white plaques accompanied by pruritis
and soreness. Infection may spread along the shaft of the penis and into the
groin fold.
Chronic Mucocutaneous Candidosis is a syndrome characterised by
chronic, oral candidosis and chronic, candidal paronychia (a simultaneous
presentation of URTI and cutaneous infection). In severe cases, the
infection can spread to the surface of the trunk and limbs (Hay - cited in
Noble, 1993). This rash is characterised by a slightly elevated margin. In
some instances, there is marked hyperkeratosis (over-proliferation of the
cornified epithelium) and epithelial hyperplasia (increase in epithelial cell
number). There is generally an immunocompromising condition underlying
the development of the infection. Patients with chronic mucocutaneous
candidosis may develop superimposed dermatophytosis or papilloma virus
infections. Other complications of long-term infection include candidal
oesophagitis and stricture formation. Squamous cell carcinomas of the
mouth have been recorded in some patients with chronic mucocutaneous
candidosis, especially if they are smokers
(Hay - cited in Noble, 1993).
2.2.2 Streptococcal skin infections
Streptococcus pyogenes remains a major cause of direct skin infection (Hay
- cited in Noble, 1993).
"Streptococcal pyoderma" is a term used to describe purulent skin infections
and includes streptococcal impetigo, together with other pustular
streptococcal infections such as otitis externa, angular cheilitis, paronychia
and infections in tattoos and pierced ear lobes (Barnham - cited in Noble,
1993).
Superficial impetiginous lesions (pyoderma) tend to develop on damaged
and exposed areas of the skin. Initially, small erythematous papules
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develop, which evenutally become pustular then form thick honey-coloured
crusts form on an erythematous base (Barnham - cited in Noble, 1993).
These lesions eventually coalesce and may be accompanied by moderate,
tender lymphadenopathy. Untreated lesions can persist for several weeks,
shedding large numbers of bacteria into the environment, before healing
without a scar. This form of infection occurs commonly in young children
and tends to be prevalent in poor socio-economic communities (Barnham -
cited in Noble, 1993).
Before the streptococcus can initiate an infection, the skin must be
traumatised in some form or other, e.g. cuts, insect bites, abrasions. This is
especially evident in patients who have had previous colonisation of healthy
skin.
Using contaminated fingernails to scratch insect bites could result in the
implantation of streptococci in the affected area.
Ecthyma refers to a deeper, more tenacious form of ulcerated pyoderma.
The clinical presentation is a raised, oedematous edge with a hard, adherent
crust. These lesions occur singly or in groups, most frequently on exposed
areas of the lower extremities.
Secondary cutaneous infections can occur in the rashes of scabies,
dermatophytosis, eczema and similar conditions, when they become infected
with streptococci. In some patients, the colonisation by this organism is
asymptomatic. Varicella (chickenpox) lesions, which become infected with
streptococci, can lead to serious invasive disease.
Infective dermatitis, a chronic form of infected eczema, was identified in
Jamaican children. It was found that these lesions commonly yielded beta-
haemolytic streptococci or Staphylococcus aureus. The human T-
Iymphotrophic virus type 1 has also been associated with this type of
infection (Barnham - cited in Noble, 1993).
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Colonisation of burns with Group A, C or G streptococci can be
asymptomatic in some patients. In such patients, there may be a failure of
skin engraftment. However, there are other patients who will experience
more seriously invasive effects (Barnham - cited in Noble, 1993).
Research has show that, if foreign material is present in a wound, then a
much smaller inoculum of S.pyogenes is necessary to initiate infection. This
has been attributed to decreased coating of the infecting organism with
opsonin. Opsonisation is the process by which an infecting agent is coated
with this antibody or complement -split product before being presented to the
leukocytes and other macrophages for phagocytosis (Glanze, Anderson,
Anderson. 1990). In addition to this, the bacteria adhere to the foreign
material, making them less accessible to the host's defence system.
Streptococcal infections in deeper wounds can lead to a rapidly, spreading,
painful, deep inflammation termed cellulitis. This condition is characterised
by erythema and oedema. The danger of cellulitis is that it can progress to
local lymphatic spread, culminating in septicaemia if not properly treated
(Barnham - cited in Noble, 1993).
Though uncommon, it is important to note subcutaneous abscesses and
superficial bullae are sometimes local complications that can be seen in
patients with cellulitis (Barnham - cited in Noble, 1993).
Ultimately, contamination of wounds with streptococci produces results that
can range from symptomless colonisation to a rapid, systemic spread, often
with minimal inflammation at the original site. It is important to take note of
factors such as the extent, depth and site of the wound. In addition, the
presence of necrotic tissue or foreign materials within the wound itself is very
important.
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Erysipelas is an acute, erythematous lesion that is associated with
subepidermal spread of the infection (Noble, 1993). It most commonly
occurs on the face, especially in patients with URTls. The lesions can occur
elsewhere on the body. This disease is mainly seen in the elderly. There
is oedema and a rapidly advancing margin of the lesions. The appearance
of the characteristic lesions has partly been explained as being due to a
hypersensitivity reaction to streptococcal by-products (Barnham - cited in
Noble, 1993).
Recurrent forms of erysipelas and cellulitis are also found to occur in
patients suffering from lymphatic obstruction or vascular obstruction.
Necrotising fasciitis (synergistic necrotising cellulitis) refers to a severe
infection that causes both subcutaneous tissue and fascia (connective tissue
sheath) to undergo necrosis (Berkow, Fletcher, et al., 1987).
S.pyogenes may, on occasion, be the sole initiator of this disease; however,
it is more often associated with a mixture of aerobic and anaerobic bacteria.
This disease could be a sequela of a seemingly trivial injury to the skin. The
initial presentation is usually cellulitis, which rapidly develops into a deeper-
seated necrosis. There is a great risk of septicaemia and rapid death. This
disease is mainly seen in older patients, who have a pre-existing medical
disorder (Barnham - cited in Noble, 1993).
Miscellaneous secondary streptococcal infections
• Spyogenes may colonise areas such as the umbilicus of neonates and
older persons. In some instances, inflammation of the umbilical stump of
neonates results in redness, swelling and purulent exudate being formed.
This condition is referred to as omphalitis (Berkow, Fletcher, et al;
1987). If not adequately treated, septicaemia could result.
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• Keratoconjunctivitis and acute guttate psoriasis can be further
candidates for secondary streptococcal infection. The latter condition
occurs in children and young adults and is frequently preceded by a
streptococcal sore throat. ((Barnham - cited in Noble, 1993).
• Post-streptococcal glomerulonephritis (PSGN) is another
complication of streptococcal infection. This disease is more commonly
preceded by a streptococcal skin infection, such as impetigo, rather than
an URTI. Unlike rheumatic fever, PSGN does not become reactivated
with recurrent streptococcal infections. It is claimed that the pathogenic
agent responsible for PSGN is 'nephrostreptokinase' (NSAP) (Barnham -
cited in Noble, 1993). Other substances that have been implicated are
endostreptosin (ESS) and pre-absorbing antigen.
It is thought that, when NSAP binds to the glomerular basement membrane,
the following sequence of events occurs; plasminogen activation, antibody
and complement deposition at the basement membrane and subsequent
infiltration of inflammatory cells to the site leads to disruption of glomerular
function.
In addition, cross-reactions have been described between streptococcal M-
protein and renal glomerular membrane (Barnham - cited in Noble, 1993).
The clinical picture presenting at this stage is haematuria, proteinuria,
oedema, hypertension and nitrogen retention. A few patients die, but some
go on to develop chronic glomerulonephritis, which ultimately results in
kidney failure (Berkow, Fletcher, et a/., 1987).
2.3 Treatment of CANDIDA and STREPTOCOCCUS infections
In regard to streptococcal infection, almost all Group A, f3-haemolytic
streptococci are sensitive to low doses of penicillin G. Generally, if the
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patient is allergic to penicillin, erythromycin or cephalexin is substituted
(Provine, Gardiner, 1984).
Candida infections are usually responsive to nystatin, amphotericin B or the
imidazoles (Jawetz, Melnick, et al., 1987) as well as new generation
antifungal agents.
There are certain instances when pathogens become genotypically or
phenotypically resistant to the antimicrobial agent (Provine, Gardiner, 1984).
Furthermore, superinfections sometimes occur during antimicrobial treatment
for another infection, e.g. Candida can flourish during penicillin therapy for a
bacterial infection (Glanze, Anderson & Anderson, 1990).
From a homoeopathic approach, Echinacea can be used to advantage in the
treatment of URTls and cutaneous infections. In acute illness, if Echinacea
is taken early on, it can effectively arrest the progression of the illness.
However, in cases of infection where the in vivo titre of the pathogen is so
high that the immune system cannot cope on its own, it would be prudent to
use Echinacea as an adjuvant to allopathic antibiotics. Using this approach,
the antibiotics can serve to reduce the number of organisms, while the
Echinacea simultaneously boosts the immune system.
In the interest of clarity, it is important to note that there are certain instances
when antibiotics can fail to act effectively. An example of this would be if an
organism is in a dormant phase, because many antibiotics act only on
actively growing bacteria.
Another example is when the failure of the antibiotic has been attributed to
protection of the pathogen by other constituents of the host flora that
produce drug-inactivating enzymes; e.g. protection of Group A, ~-haemolytic
streptococci from penicillin by penicillinase producing Staphylococcus
aureus (Glanze, Anderson & Anderson, 1990).
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According to Foster (1991), Baetgen in 1988 had reported that the use
Echinacea injections to treat children with viral infections of the URT, had
shortened the duration of the illness compared with allopathic treatment
methods. However, when antibiotics were used in conjunction with
Echinacea injections in the treatment of URTls in children, improvement took
significantly longer.
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3.0 MATERIALS AND METHODS
3.1 Materials
3.1.1 Source of organisms
Pure cultures of Candida albicans and Streptococcus pyogenes were
obtained from Bruinette and Kramer Pathology Laboratories within the
Gauteng area. The organisms were isolated from specimens of patients.
Twenty strains of each organism were employed in this study.
3.1.2 Culture maintenance
The regular maintenance of stock cultures is vital in order to prevent
contamination, mutation or death of the organisms.
3.1.3 Long-term stock cultures
C.albicans and S. pyogenes were maintained on sterile, skim milk medium at
-18°C.
3.1.4 Short-term stock cultures
C.albicans was maintained on Sabouraud's Dextrose Agar (SDA) slopes.
S.pyogenes was kept on Nutrient Agar (NA) slopes. The S.pyogenes strains
were subcultured on to Blood Agar (BA) plates for daily use. SDA plates
were used for C.albicans.
3.1.5 Media for experimentation
Cultivation of S.pyogenes
• Serum Broth (SB) for tube potency tests.
• BA (horse blood) for disc diffusion tests.
Cultivation of C.albicans
• SDB* for tube potency tests.
• SDA* for disc diffusion tests.
• Both these media are suitable for sensitivity testing of fungi.
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3.1.6 Standardisation of inoculum
McFarland Standards were made at the Technikon Witwatersrand according
to the formulation set out in the Clinical Microbiology Procedures Handbook
(1992). These standards were used to prepare suitable culture inocula.
3.1.7 Antibacterial and antifungal agents
Control discs containing 100 units of nystatin were used when testing
C. albicans.
01-1
Figure 3.1 Molecular structure of Nystatin
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Control discs containing 25 units of ampicillin were used when testing
S.pyogenes.
H H CH3S
CHCONH
I CH3
NH2 N
0 COOH
Figure 3.2 Molecular structure of Ampicillin
3.1.8 Consumables
Micropipettes with disposable tips were used for all dilutions and inoculation
procedures.
3.1.9 Tinctures
Echinacea angustifolia (Ea), E. purpurea (Ep) (both are Simplexes) and
Echinacea angustifolial E. purpurea (Ea/Ep) Complex in mother tincture (MT)
and the potencies of 3CH, 9CH and 15CH were used.
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3.2 Methodology
Two standard methods were employed to determine the susceptibility of the
test microorganisms to chemotherapeutic agents, namely the tube dilution
test (TOT) and the disc diffusion test (DDT) as per Boyd (1988).
However, for the purpose of this study, the TOT was modified to the tube
potency test (TPT) as homoeopathic substances, unlike general
chemotherapeutic agents, were being tested.
All procedures were carried out separately and in triplicate for each test for
the 2 test organisms.
3.2.1 Tube potency test
This is a quantitative, in vitro susceptibility test, which was used to determine
the maximal effective potency (MEP) of both Eangustifolia and Epurpurea,
as single substances and in combination as a complex substance.
3.2.2 Disc diffusion test
This is a qualitative, antimicrobial sensitivity test, using solid media and is
recommended by the Food and Drug Administration (FDA) of the USA
(Boyd, 1988).
3.2.3 Testing of microorganisms
Both organisms were studied in each test, TPT and DDT, using the
homoeopathic preparations listed at the stated potencies. The control
chemotherapeutic agents were the antifungal agent, nystatin against the
yeast, C.albicans and the antibiotic, ampicillin against the Gram-positive
bacterium, S.pyogenes.
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3.3 Phase 1 - Construction of standard growth curves
Standard growth curves (SGC) were constructed for each test organism by
plotting the optical density (00) readings against colony counts obtained
from the tube dilutions of 5 of 20 randomly selected strains of each
organism.
3.3.1 Standard suspensions
The suspensions of C.albicans and S.pyogenes were standardised against a
0.5 McFarland Standard. Standardisation was done visually, comparing the
turbidity of the suspensions with the turbidity of the McFarland standard over
a Wickerham card. This gave a subjective indication of the turbidities of the
suspensions in relation to the standard.
If adjustments were necessary, sterile distilled water was added aseptically
to the candidal suspensions and sterile saline to the streptococcal
suspensions, until the turbidities were comparable to that of the McFarland
standard.
3.3.2 Optical density
Serial dilutions of the order of 10 -6 were made from the standard
suspensions of C.albicans and of S.pyogenes according to the following
steps (Fig. 3.3).
1 Using a sterile pipette, one millilitre (ml) of the standard suspension
was aseptically transferred to 9 ml of sterile broth in tube A.
2 Tube A was vortexed to ensure thorough distribution of the inoculum
through the broth.
3 1 mf of the suspension from tube A was transferred to 9 mf broth in
tube B.
4 This dilution procedure, steps 1 to 3, was sequentially repeated to
tube F.
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Figure 3. 3 Serial dilution (0 0) and plate-out (cfu/ml) techniques for C.albicans
and S.pyogenes to obtain Standard Growth Curves (SGC) for the test organisms.
This dilution method produced a logarithmic dilution series as follows:
Logarithmic dilution series
Tube A 10 .1
Tube B 10 .2
Tube C 10 -3
Tube 0 10 -4
Tube E 10 -5
Tube F 10 -6
New ste rile pipette tips were used for each strain of the organisms and each
series was replicated in tr ipl icate .
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3.3.3 Determination of optical density
Spectrophotometric readings were performed at 560 nanometers (nm). The
spectrophotometer was tared using a blank cuvette containing the broth
appropriate to the organism under test.
0.5 mt of each dilution of the organism was transferred to a clean cuvette
and OD readings was taken. The readings were determined from the
highest to the lowest dilutions to prevent carry-over of organisms between
dilutions, which could have yielded inaccurate readings. New pipette tips
were used between each dilution series.
3.3.4 Determination of colony counts
0.1 mt from each dilution tube was plated out on to an agar plate,
appropriate to the test organism. The inoculum was spread evenly over the
surface of the plate using a 'hockey stick' applicator.
The plates were incubated at 37°C. C.albicans grew well after 24 hours
incubation, but S.pyogenes required 48 hours incubation to obtain adequate
colony size. Colony counts were obtained using a digital colony counter.
The data obtained were used to construct separate SGC for C.albicans and
S.pyogenes, by plotting OD readings against colony counUmf for each
dilution.
These SGC were used to convert all OD readings obtained in the Phase 2
studies into colony forming units per milliliter of suspension (cfu/mf).
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3.4 Phase 2 Effect of homoeopathic remedies on the growth of
C.albicans and S.pyogenes in vitro
3.4.1 Tube potency test - Test series
Test series 1 C.albicans and Ea
C.albicans was cultured on SOA or SOB as appropriate. The TPT was
modified with respect to the construction of the dilution series for OD
determinations. Each tube had a standard, final volume of 5 rnt (Table 3.1).
All inoculated tubes were vortexed to ensure thorough mixing of the
"'SIIsperlstunscmtl· were: incdbatet.l-a t'E71°'C4'foT'2i+ 'tIDers. 1ffter;ir1ct\t:1c1hun,
each tube was examined for the visual end point of microscopic growth and
OD readings made. OD readings were read on the relevant SGC to obtain
colony count values; these data conversions were effected automatically by
the software programme used.
Table 3.1: Test Series 1 - C.albicans vs Ea, TPT set up.
Test tube No. Broth me Potency Volume mt Inoculum me
T1 -ve control 5 0 0 0
T2 +ve control 4.75 0 0 0.25
T3 4.5 MT 0.25 0.25
T4 4.5 3CH 0.25 0.25
T5 4.5 9CH 0.25 0.25
T6 4.5 15CH 0.25 0.25
50
5.0 ml broth 4.75ml broth 4.5 ml broth asfor as for as for
0.0 ml inoc 0.25ml inoc 0.25 ml ptcy T3 T4 T50.25 ml inoc
Tl T2 TJ T4 15 T6
MT 3CH 9CH I!iCH
-v e control f ve contrul
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Figure 3.4 Tube Potency Test - set up format
Test series 2 - C.albicans and Ep
Dilutions were made as for Test Series 1 (refer Tabl e 3.1) as well as colony
count values as for Test Series 1.
Test series 3 - C.albicans and EaJEp Complex
Dilutions were made as for Test Series 1 (refer Table 3.1) as well as colony
count determinations as for Test Series 1.
Test series 4 - S.pyogenes and Ea
Dilutions were made as for Test Series 1 (refer Table 3.1) as well as colony
count determinations as for Test Series 1.
51
Test series 5 - S.pyogenes and Ep
Dilutions were made as for Test Series 1 (refer Table 3.1) as well as colony
count determinations as for Test Series 1.
Test series 6 - S.pyogenes and EaJEp Complex
Dilutions were made as for Test Series 1 (refer Table 3.1) as well as colony
count determinations as for Test Series 1.
3.4.2. Disc diffusion test
3.4.2.1 Section 1 - Preparation of standardised, impregnated discs
0.5 mt aliquots of each of the homoeopathic test substances were
transferred to sterile, capped specimen bottles using fresh, sterile pipette
tips for each of the different test substances and different potencies of each
(Table 3.2).
Twenty blank discs were transferred aseptically into each of the capped
bottles using a sterile needle. The bottles were left at room temperature with
the caps loosened, in order to allow the impregnated discs to dry thoroughly.
The bottles, with tightened caps, were stored at 2 - 8 °C prior to use.
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Table 3.2 - Preparation of standardised, impregnated discs
Bottle No. Remedy Potency Volume me
81 Ea MT 0.5
82 Ea 3CH 0.5
83 Ea 9CH 0.5
84 Ea 15CH 0.5
85 Ep MT 0.5
86 Ep 3CH 0.5
87 Ep 9CH 0.5
88 Ep 15CH 0.5
89 Ea/Ep MT 0.5
810 Ea/Ep 3CH 0.5
811 Ea/Ep 9CH 0.5
812 Ea/Ep 15CH 0.5
3.4.2.2 Section 2 - Preparation of test series
Test series 1 C.albicans
0.1 mt of standardised suspension of each strain of C.albicans was seeded
on to separate SDA plates, utilising sterile pipette tips. The tips were
changed between each strain. The inocula were spread evenly over the
SDA plates using the 'hockey stick' applicators.
The surface of the agar in the plates was allowed to dry at room temperature
before the impregnated discs were aseptically transferred to them (Fig. 3.5)
in the order shown in Table 3.3.
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Table 3.3 Disc diffusion test (DDT) set up
Plate No. Disc No. Remedy Potency
1 1 Ea MT
2 Ea 3CH
3 Ea 9CH
4 Ea 15CH
5 control 100 units
2 1 Ep MT
2 Ep 3CH
3 Ep 9CH
4 Ep 15CH
5 control 100 units
3 1 Ea/Ep MT
2 Ea/Ep 3CH
3 Ea/Ep 9CH
4 Ea/Ep 15CH
5 control 100 units
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MT mother tincture
J 3CH
9 9CH
15 15CH
C Il ytit.fttin 100 unlts
(~)
Figure 3.5 - Disc diffusion plate set up - C.albicans [C was nystatin 100 units]
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Test series 2 S.pyogenes
The procedure shown in Table 3.3 was set up for S.pyogenes; the only
difference being that SA plates were used and ampicillin 25 units served as
the control (Fig. 3.6).
Key
It.AT molhe r Iinctu re
3 JCH
9 90i
15 15CH
C ampici lli n 25 units
Figure 3.6 - Disc diffusion plate set up - S.pyogenes [C was ampicillin 25 units)
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4.0 RESULTS
4.1 Standard Growth Curves for C.albicans and S.pyogenes
The data obtained from the twenty strains of each species was used to
construct the standard growth curves (SGCs) for the test organisms. These
SGCs are illustrated for C.albicans in Fig. 4.1 and for S.pyogenes in Fig. 4.2.
The cfu/ml counts for each organism were calculated from the SGCs via the
statistical programme used at TWR.
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Figure 4.1 SGC for C.albicans
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Figure 4.2 SGC for S.pyogenes
4.2 Disc diffusion method
No zones of microbial inhibition were produced around the discs that were
impregnated with Ea, Ep and Ea/Ep Complex in MT and the various
potencies tested (Appendix A). This was true for both of the test organisms,
C.albicans (Fig. 4.3) and S.pyogenes (Fig. 4.4).
However, neither was there any evidence of increased growth around the
discs.
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There are several factors that could have contributed to the results of this
experiment.
First, the possibility that this particular method, which is designed to test
allopathic medicines, may not be sensitive enough to test homoeopathic
medicines, because of the degree of deconcentration that they have
undergone.
Secondly, the diffusion process could have been influenced by the size of
the diffusing molecules. It is possible that the molecules of the active
principles are too large to diffuse out adequately (Guyton, 1984).
Thirdly, the solubility of the active principles also needs to be looked at. If
these are hydrophobic, it could account for the apparent lack of diffusibility.
Fourthly, as has been previously noted, the various test solutions contain
quite a number of compounds. If some of the compounds diffused out
without the others, there could be a loss of effect. It has already been
mentioned that the total extract is more effective than any isolated
component of the extract (Harnischfeger, Stolze, 1980).
Using chromatography, one would be able to assess the diffusion rates of
the various constituents and this may be useful in the design of future test
systems for these homoeopathic remedies.
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Figure 4.3 DDT for C.albicans
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Figure 4.4 DDT for S.pyogenes
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4.3 Tube potency test
In view of the disc diffusion test not providing satisfactory results, it was
proposed.that the TPT was probably more suitable for testing of
homoeopathic medicines, because the test organisms are bathed in the test
solutions. This results in the organisms being in direct contact with the
active principles within the test medication.
The form of statistical analysis that was employed in the TPT was a One-way
Analysis of Variance (ANOVA) with a comparison between the absorbance
values of pure cultures of G.albicans and S.pyogenes and cultures of these
two organisms exposed to Ea, Ep and Ea/Ep Complex in MT and potencies
of 3CH, 9CH and 15CH. Dunn's method was used to make the comparison
(Personal communication - Mr N de Villiers, TWR), (Appendix B).
From the results, it is evident that there was no direct inhibitory effect of any
of the test medications on G.albicans.
Interestingly however, the following observations were noted.
Ea and Ea/Ep Complex had zero growth effect on C.albicans, but the higher
9CH and 15CH potencies of Ep actually stimulated significantly the growth of
this organism (Figs. 4.1 - 4.3 and Table 4.1).
Table 4.1 Effect of Ea, Ep and Ea/Epin MT, 3CH, 9CH and 15CH on the
growth of G.albicans in vitro
Potency No difference* Stimulation Inhibitory
Ea MT, 3CH, 9CH, 15CH Nil Nil
Ep MT,3CH 9CH,15CH Nil
Ea/Ep MT, 3CH, 9CH, 15CH Nil Nil
* Compared to positive control
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Figure 4.5 TPT for Ea against C.albicans
9CH 15CH
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Figure 4.6 TPT for Ep against C.albicans
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Figure 4.7 TPT for Ea/Ep against C.albicans
The results for S.pyogenes were markedly different. Notably, all potencies
of Ea and Ea/Ep Complex stimulated the growth of S.pyogenes as well as
the MT of Ep. The 3CH and 9CH potencies of Ep had no growth effect, but
15CH potency of Ep elicited a markedly inhibitory effect on the growth of
this organism (Figs. 4.8 -4.10 and Table 4.2).
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Table 4.2 Effect of Ea, Ep and Ea/Ep in MT, 3CH, 9CH and 15CH on the growth
of S.pyogenes in vitro
Potency No difference* Stimulation Inhibitory
Ea 3CH,9CH MT 15CH
Ep Nil MT, 3CH, 9CH, 15CH Nil
Ea/Ep Nil MT, 3CH, 9CH, 15CH Nil
* Compared to positive control
These varied responses between the species are associated in part by the
fact that these two test organisms are genotypically and phenotypically
distinct.
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Figure 4.8 TPT for Ea against S.pyogenes
9CH 15CH
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Figure 4.9 TPT for Ep against S.pyogenes
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Figure 4.10 TPT for Ea/Ep against S.pyogenes
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5.0 DISCUSSION
Echinacea has received worldwide acclaim for what had been termed its
"immunostimulatory" and "antimicrobial" properties (Ody, 1993).
Extensive research has provided evidence to support the immunostimulatory
effects of Echinacea. It has been noted by Bauer, Remiger (cited in
Schulthess, Giger, Baumann, 1991), that the methylbutamines of ell and C16
alkenes and alkynes, found in Echinacea, playa pivotal role in
immunostimulation.
Further testing has also shown that purified polysaccharide fractions (PPF)
of Ep stimulate macrophages to secrete natural immune response proteins
such as TNF-a, IL1 and IL6.
Roesler and co-workers (1991a) also state that these PPFs of Ep enhance
the phagocytic activities of macrophages, both in vivo and in vitro.
In a controlled study, it was noted that mice, which were injected with PPFs
of Ep prior to being inoculated with C.albicans, did not develop systemic
infection and that their liver Kupfer cells showed greater inhibitory effects
against C.albicans compared to the control group. This protection was
attributed to enhanced migration of PMN cells in the peripheral blood.
The exact mechanism by which Echinacea elicits this immunostimulatory
response is not yet fully understood, but Burger, Torres, et al., (1997)
maintain that the activation of cytokine pathways plays a pivotal role in this
process.
With regard to the antibacterial and antifungal properties that have been
attributed to Ea and Ep, this investigator has not found any reports in the
English language literature of in vitro qualitative nor quantitative
antimicrobial tests being carried out on Ea, Ep or Ea/Ep Complex in support
of these assertions.
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The definitions of "antifungal" and "antimicrobial", respectively, refer to any
agent which kills fungi or bacteria, or which inhibits their growth and
replication (Glanze, Anderson & Anderson, 1990).
Schulthess, Giger & Baumann (1991) have stated that polyacetylenes
isolated from the Echinacea plants, do possess antifungal and antibacterial
properties.
In addition, echinacin, also isolated from Echinacea, is said to be
antibacterial by virtue of the fact that it is a hyaluronidase antagonist
(Budavari, O'Neil, Smith, 1989).
Hyaluronidase is an enzyme that serves as a virulence factor, not only in
S.pyogenes, but also in certain other pathogens. It hydrolyses hyaluronic
acid, which is the connective tissue ground substance found in intercellular
spaces: this allows the organism to migrate through the tissues (Jawetz,
Melnick, et a/., 1987).
Information about the polyacetylenes and echinacin does not tell us much
about-the possible antimicrobial effects of the total extract of the Echinacaea
plant. The significance of this information concerning individual components
is being questioned, because the commercially available Echinacea
products are made from the total extract. The total extract is composed of a
number of different constituents, including inulin, betains,
methyltetradecadiene, resins and fatty acids (Budavari, O'Neil, Smith, 1989).
Harnischfeger & Stolze (1980) affirm that the total extract of Echinacea
exhibits greater therapeutic efficacy than any isolated active principle.
These observations relate to the immunomodulatory activity of Echinacea. It
is not clear whether this statement can also be applied to possible
antimicrobial effects of the plant extract. These workers also state that the
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PPFs of Ep help prevent viral penetration into the host cell by helping to
maintain the integrity of the cell membrane.
To be certain, synergy studies would need to be carried out to assess
whether the various components act together and, if so, whether they
function additively, synergistically or antagonistically compared to the
polyacetylenes and echinacin alone.
The quality of plant medicines can be affected by several factors, notably the
growth environment, for example, plants growing in dry, low nitrogen soils
produce higher concentrations of essential oils, whereas those growing in
moist, nitrogen-rich soils produce higher alkaloid levels. Similarly, the time
of day when plants are harvested also affects the quality of the chemical
constituents. It may be important to consider these factors, as there are no
standard methods set out for the cultivation of the plants and subsequent
therapeutic claims of the products. Such studies would be highly labour
intensive and costly, so somehow a middle road has to be found to obtain
the maximum therapeutic effects.
The current study attempted to determine the in vitro efficacy of the full plant
extracts of Ea and Ep (Simplexes) and the complex Ea/Ep against two
microorganisms commonly encountered in a homoeopathic practice, namely
the fungus G.albicans and the bacterium, S.pyogenes.
Various potencies of Echinacea preparations marketed as OTC products
were tested for their antifungal and antibacterial activity using the disc
diffusion method (DDT) and an adaptation of the standard tube dilution
method termed the 'tube potency method' (TPT). The DDT is a qualitative
antimicrobial sensitivity test using solid media and recommended by the FDA
(Boyd, 1988). The latter is a quantitative, in vitro susceptibility test used to
determine the maximal effective potency (MEP) of the test medicines.
The results obtained are discussed in the following sections.
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In the disc diffusion test, no zones of microbial inhibition were produced
around the discs that were impregnated with Ea, Ep and Ea/Ep Complex in
MT and the various potencies tested (3CH, 9CH and 15CH). This was true
for both of the test organisms, C.albicans and S.pyogenes. However, neither
was there any evidence of increased growth around the discs.
There are several factors that could have contributed to the results of this
experiment.
First, the possibility that this particular method, which is designed to test
allopathic medicines, may not be sensitive enough to test homoeopathic
medicines, because of the degree of deconcentration that they have
undergone.
Secondly, the diffusion process could have been influenced by the size of
the diffusing molecules. It is possible that the molecules. of the active
principles were too large to diffuse out adequately (Guyton, 1984). It is
known that giant polymers (macro-molecules) are formed with each
succussion performed.
Thirdly, the solubility of the active principles also needs to be known. If they
are hydrophobic, it could account also for the apparent lack of diffusibility.
Bauer, Jurcic, Puhlman and Wagner, 1988 (cited in Foster, 1991) had shown
that lipophilic fractions of E.angustifolia, E purpurea and E.pallida had
stronger action than the hydrophilic fractions in the in vitro granulocyte test;
this correlated with the in vivo results of the carbon clearance by
phagocytosis in mice. Although these results relate to immunostimulatory
effects, similar principles could be involved in antimicrobial efficacy.
Fourthly, as has been previously noted, the various test solutions contain
quite a number of compounds. If some of the compounds diffused out
without the others, there could be a loss of effect. It has already been
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mentioned that the total extract is more effective than any isolated
component of the extract (Harnischfeger, Stolze, 1980).
Using chromatography, such as HPLC, one would be able to assess the
diffusion rates of the various constituents and this may be useful in the
design of future test systems for these homoeopathic remedies.
In view of the disc diffusion test not providing satisfactory results, it was
proposed that the TPT might be more suitable for testing homoeopathic
medicines, because the test organisms are bathed in the test solutions and
so are in direct contact with the active principles within the test medication.
It is emphasised that all medications used in this study were manufactured
from total plant extracts.
The form of statistical analysis that was employed in the TPT was a One-way
Analysis of Variance (ANOVA) with a comparison between the absorbance
values of pure cultures of C.albicans and S.pyogenes and cultures of these
two organisms exposed to Ea, Ep and Ea/Ep Complex in MT and potencies
of 3CH, 9CH and 15CH. Dunn's method was used to make the comparison
(Personal communication - Mr N de Villiers, TWR).
From the results, it is evident that there are quite different effects of the test
medications on the fungus, C.albicans compared to those on the bacterium,
S.pyogenes.
The results obtained in this study indicated that, in vitro, none of the test
medicines significantly inhibited the growth of G.albicans.
The Ea and Ea/Ep Complex in all potencies and Ep in MT and 3CH
potencies had zero growth effect on C.albicans when compared to the
positive control.
The higher, 9CH and 15CH potencies of Ep actually stimulated significantly
the growth of this fungus.
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The addition of Ea to Ep to form the complex, Ea/Ep, resulted in the 9CH
and 15CH potencies of Ep no longer exerting a stimulatory effect.
This suggests that there is possibly an antagonistic relationship between Ea
and Ep at those particular potencies against C.albicans. This merits further
investigation.
These observations generate other queries. For example, the fact that at all
potencies tested for Ea Simplex and Ea/Ep Complex showed no observable
growth effect compared to the positive control, indicates potencies of greater
than 15 CH need to be tested to determine whether they exert a direct
antifungal effect on this fungus.
In particular, the use of Ep alone at 9CH and 15CH potencies for the
treatment of candidal infections may be contraindicated, as they are
stimulatory.
In this situation, an alternative could be to use Ea product in preference,
although this extract, at all the potencies tested, had no overt, direct
antifungal effect compared to the positive control. Can it, therefore, be
claimed to have antifungal properties at these potencies. Higher potencies
need to be tested to determine whether the Arndt-Schulz Law is being
obeyed.
More important, could this scenario also hold true for the treatment of
mycotic infections in general? Again, further study is warranted to try to
resolve the question.
All potencies of Ep Simplex, Ea/Ep Complex and the MT of Ea Simplex
stimulated the growth of S.pyogenes, whereas only the 3CH and 9CH
potencies of Ea Simplex elicited neither growth stimulatory nor growth
inhibitory effects on this organism when compared to the positive control.
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The potency 15CH Ea exerted significant inhibition on the growth of
S.pyogenes. This appears to concur with the Arndt-Schulz Law, which states
that minute stimuli (low potencies) stimulate physiological activity as shown
by an increase in biomass, while large stimuli (high potencies) inhibi,t or halt
physiological activity, which can be manifest as a decrease in biomass.
McKenna (1996) observed, that in clinical practice, the Ea/Ep Complex
appears to have a greater therapeutic efficacy than either Ea or Ep used as
Simplexes.
In contrast, the results from this study suggest that Ep Simplex and Ea/Ep
Complex should be avoided as direct antibacterial products as all tested
potencies of these compounds showed stimulatory growth effects in vitro.
Further investigations are required to clarify the usage situation with respect
to S.pyogenes.
It will be interesting to pursue these combined studies using higher
potencies of the various simplex and complex compounds of Echinacea to
determine whether true synergy or antagonism is occurring.
These additional observations may have an impact on homoeopathic
therapeutics as currently practised, for example, in the case of C.albicans,
the Ep simplex at 9CH and 15CH potencies was stimulatory, whereas the
addition of Ea to Ep to form the Ea/Ep Complex resulted in the 9CH and
15CH potencies of Ep no longer having a stimulatory effect. An antagonistic
relationship between Ea and Ep Simplexes is suggested at those particular
potencies for that particular fungus.
If further investigation shows this to be true, then the use of Ep alone at 9CH
and 15CH potencies for the treatment of candida I infections should be
contraindicated. Similarly, the alternative might be to use Ea or an Ea/Ep
Complex in preference, but these have been shown to exert no growth effect
compared to positive Candida controls. Theoretically this would be neither
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therapeutically nor cost effective. Ethical considerations could impinge at
this point.
Moreover, if one considers commercial production costs, it may be more
cost-effective to use a Simplex at higher potencies, rather than a Complex if
one is seeking a direct antifungal effect.
Could these observations also hold true for the treatment of other mycotic
infections, such as ringworm, encountered in the general homoeopathic
practice? Further study is required to answer some of these questions.
Conversely, in the case of S.pyogenes, it appears that it may be more
prudent to use Ea at 15CH as it inhibited the growth of the bacterium, rather
than any lower potencies of that Simplex.
Similarly, all potencies of Ep and Ea/Ep Complex tested stimulated the
growth of the bacterium and may contraindicate general usage for direct
antibacterial treatment.
More important, at 3CH and 9CH potencies of Ea, no observable growth
effect was noted compared to the control, so should these potencies be
claimed to be antimicrobial? Potencies greater than 15 CH need to be
tested to determine whether they exert a direct inhibitory effect on this
bacterium.
The data obtained in this study when tested by the Dunn's Comparison was
inconclusive in this regard. Investigations using higher potencies in well-
designed TPT and chequerboard studies are warranted.
In terms of patient care, the growth stimulatory effects of potencies
commonly available over-the-counter (OTC) could be undesirable if the Ep
or Ea/Ep Complex was being taken as a general immunostimulant, while the
patient was suffering from a fungal or bacterial infection. For example, a
patient may be unaware that they have such an infection, as with an
asymptomatic streptococcal sore throat (Barnham, cited in Noble, 1993). In
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such cases, the organism may proliferate more rapidly, before the immune
response could react positively to the immunostimulation of the product.
The stimulatory effect elicited by the various potencies of the Simplexes and
Complex appears to relate to the pharmacological principle of hormesis,
which refers to the fact that a reversal of biological effect can be observed at
various ranges of concentration of the same medicinal substance (Gaier,
1991).
If direct antifungal and antibacterial claims are to be made, it would be
beneficial to conduct synergy studies in order to determine conclusively
whether the relationship between Ea and Ep Simplexes and the Ea/Ep
Complex could be additive, synergistic or antagonistic against
microorganisms at higher potencies (above 30CH). Potencies of 100CH and
above, which would normally only be available on prescription from a
registered homoeopathic practitioner, may be found to exert direct'
antimicrobial action against a range of organisms.
Additional observations indicated that the results obtained for C.albicans at
the potencies of 9CH and 15CH for Ep, seemed to correspond to the
principle of hormesis also.
Therapeutically, this suggests that these potencies should not be used for
antifungal purposes alone and possibly not for immunostimulation without
other antifungal cover when patients are infected with this fungus.
Proliferation of the yeast could occur before immunostimulation had an effect
and so retard the recovery of the patient.
From this study, the only medicine seen to have any direct antimicrobial
effect in vitro is Ea 15CH against S.pyogenes. This potency would appear
not only to boost the immune system in cases of streptococcal infection, but
it could have the added advantage of inhibiting the growth of the pathogen.
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It would be remiss not to extend these investigations using higher potencies,
because this could provide valuable information about cut-off points at which
stimulatory effects cease and possible inhibitory effects begin. It would also
be beneficial to use different, related test organisms (i.e. other species of
Candida and of Streptococcus) in order to determine whether they respond
to the medicines in a group specific manner.
From this study, it appears that S.pyogenes was more readily stimulated in
vitro by the medicines than C.albicans. These varied responses are possibly
associated with the fact that these two test organisms are genotypically and
phenotypically distinct and therefore may metabolise the active principles via
different metabolic pathways.
The new information gathered from this study indicates that it may be
necessary to consider modification of the information provided on the
package inserts of OTe Echinacea products, because, from results obtained
in these in vitro studies, in certain instances, their use could be
contraindicated as 'specific, direct antimicrobials.
It is also evident from these results that it is necessary to have a standard
protocol established for the testing of possible direct antimicrobial effects of
homoeopathic medicines. It will then be possible to re-evaluate which
potencies should be available OTC and which should not.
This study has indicated that MT and lower potencies of 3CH, 9CH and
15CH of Echinacea Simplexes and their Complex could have undesirable
side-effects in the efficacy of treating infective conditions due to commonly
occurring yeast and bacterial organisms. This is important, because the
current school of thought appears to be that all homoeopathic preparations
of Echinacea medicines up to 30CH can be sold OTC for both
immunostimulation and antimicrobial use.
75
It could be valuable to mention an article, which appeared in the popular
press in South Africa (Sunday Times of 25 June 2000, 'Health Watch' p 9)
stating that evidence had come to light in an Australian report that
recommends asthma and hay-fever sufferers should avoid Echinacea
products, because they have generated allergic reactions in such people.
Also UK health authorities have noted prolonged use of Echinacea products
could result in hepatotoxicity.
The sources of the Echinacea products used in the original studies were not
identified in the newspaper report as being homoeopathic or herbal
preparations, therefore the concentrations of active principles were not
known. The observation of Foster (1991) on marketed products, stated that
consumers should be aware of the ingredients of Echinacea products as
adulterants, such as Parenthium intigrifolium (Missouri snake root), are
sometimes present. The consumer may be unaware of such adulterants as
he or she is generally not in a position to have access to relevant, pertinent
scientific literature.
Another parameter that was not qualified in the newspaper report was
whether the individuals exhibiting hepatotoxicity had any pre-existing liver
disease, were on any other form of therapy or were suffering from any other
underlying compromising condition. This is interesting in view of the specific
observation by Harborne, Baxter and Moss (1997), which states that
echinacoside is said to have antihepatotoxic properties.
This article could engender within the general public an unnecessary feeling
of anxiety about the use of all OTe Echinacea products, because the
newspaper article could have taken some aspects of the original reports out
of context.
This popular article brings into the limelight the need for further scientific
research into the properties of the Echinacea species and to differentiate
between herbal and homoeopathic preparations and the specific claims
made for them.
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It also emphasises the need for critical re-evaluation of the information
provided in package inserts of homoeopathic products and the user
information included in or printed on packs of herbal products.
Such critical research may indicate the need for the inclusion of
contra indications limiting the use of and claims for some of these products,
which are readily available to the general public.
This may lead to a domino effect, whereby the current Materia Medicas may
need major revision with respect to the claims and contra indications or
warnings, which should be applied to natural products and their extracts.
Such views may be regarded unfavourably by practitioners of the Classical
School of Homoeopathy, but, as with the advancement of any branch of
medical science, long-standing systems of belief are often challenged in the
interest of providing the very best care to patients.
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6.0 CONCLUSION
Several studies have shown that the polysaccharides of Echmacea stimulate
macrophages to produce TNF-u, interleukins and cytokines, in addition to
enhancing natural killer cell activity of the peripheral blood leukocytes. This
provides substantial support for the immunostimulatory properties of the
Echinacea species on the host defences.
However, to date, little work has been found described in the English
literature by way of qualitative and quantitative antimicrobial sensitivity and
susceptibility testing to support the claims made in the literature and various
Materia Medica, that Echinacea species have direct antibacterial and
antifungal effects.
This study has shown that Ea, Ep and Ea/Ep Complex in MT and potencies
of 3CH, 9CH and 15CH do not appear to have any direct antifungal effect
against C.albicans in vitro.
Furthermore, the only antibacterial effect shown against S.pyogenes was
exhibited by Ea 15CH. This agrees with the Arndt-Schulz Law, which states
that the higher potencies tend to inhibit physiological activity.
Further interesting observations indicated Ep 9CH and 15CH stimulated the
growth of C.albicans. Also Ep and Ea/Ep Complex at all potencies, as well
as Ea MT, stimulated the growth of S.pyogenes. This seems to be in
agreement with the pharmacological principle of hormesis, which deals with
the reversal of biological effects noted at various concentrations of the same
medicinal substance.
The possibility exists that Echinacea medicines may have more than just
immunostimulatory effects in vivo under conditions of infection with
C.albicans and S.pyogenes. At certain potencies in vitro, this medicine can
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cause these organisms to proliferate; in vivo this may occur before the
immunostimulatory action has had a chance to take effect. This could hinder
the patient's recovery process.
These observations have drawn attention to the importance of developing a
standard protocol for the assessment of possible antimicrobial effects of
homoeopathic medicines at various potencies, using different organisms. It
may well be that direct, antifungal and antibacterial effects are potency
specific for the different Echinacea species.
It is evident that performance of synergy studies on the various components
of the Echinacea plant extracts from the different species could indicate how
it may be possible to enhance purely antibacterial and antifungal effects of
the medicines.
This would be helpful in the development of topical antiseptic agents.
Also, more studies on the Ea/Ep Complex will provide information on the
relationship between Ea and Ep, whether combination of the Simplexes is
additive, synergistic or antagonistic in regard to possible antimicrobial
effects. From this it will become clear when it is preferable to use the
Echinaceas as a Simplex or as a Complex for the treatment of Candida and
streptococcal infections.
The possibility exists that the OTC Echinacea products may need to be re-
evaluated microbiologically in order to assess whether there are any
additional effects that have not yet been discovered.
Ultimately it appears that the package inserts, included with the OTC
Echinacea products, may need to be updated with possible contraindications
added for the benefit of the public.
In summary, certain recommendations are made:
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6.1 Recommendations
1. Higher potencies of the Ea and Ep Simplexes and the Ea/Ep
Complex should be tested in the TPT set out in the current study
system to determine direct antifungal and/or antibacterial efficacy
in vitro against C.albicans and S,pyogenes.
2. Well-designed studies, based on the chequerboard system,
should be performed to determine whether the in vitro growth
results obtained in this study and in Recommendation No 1 for the
Ea and Ep Simplexes are unaffected when they are used as a
Complex, or whether the interactions are additive, synergistic or
inhibitory.
3. The above TPT and synergy studies should be repeated for other
species of Candida and Streptococcus to determine whether there
is a group response or whether the responses are unique for each
species tested.
4. The tests should be repeated for other genera and groups of fungi
and bacteria known to cause cutaneous and/or URT infections, for
example, the dermatophytes and the whooping cough bacillus.
5. Ethical consideration of potencies of Echinacea species showing
stimulation of growth in vitro should be carefully considered with
respect to usage as antimicrobials.
6. Reasoned recommendations on the cost-effectiveness of
formulation and use of Simplexes versus Complexes of Echinacea
could then be made.
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7. Recommendations on the promotion of formulations of Echinacea
as direct antifungal agents or antibacterial agents can be
proposed or selected warnings created. Appropriate modifications
or amendments to package inserts can then be effected.
8. Consideration of the various potencies of Echinacea can be made
with respect to the registered availability of such potencies as
OTC or prescription only for specific claims and indications.
9. In the interest of public awareness and with reference to possible
medico-legal implications, it may be advisable to supply package
inserts with all homoeopathic medicines, sourced either via OTC
or on prescription.
10. It is imperative that in vitro tests be followed by in vivo tests.
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APPENDIX A
Disc Diffusion Test data
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DISC DIFFUSION TEST (DDT) - C.alblcans vs NYSTATIN
Strain No. +veControl All potencies tested
(nystatin) zone diam. mm
zone diam. mm
la 15 0
lb 18 0
lc 12 0
2a 19 0
2b 11 0
2c 15 0
3a 15 0
3b 12 0
3c 15 0
4a 19 0
4b 15 0
4c 13 0
53 15 0
5b 18 0
5c 15 0
Sa 15 0
6b 15 0
6c 19 0
7a 15 0
7b 17 0
7c 15 0
Sa 11 0
8b 15 0
Be 16 0
9a 19 0
9b 11 0
9c 15 0
loa 15 0
lOb 15 0
lOc 11 0
11 a 13 0
11b' 11 0
11c 16 0
12a 15 0
12b 19 0
12c 17 0
13a 11 0
13b 13 0
13c 11 0
14a 13 0
14b 15 0
14c 18 0
153 11 0
15b 15 0
15c 15 0
16a 18 0
16b 19 0
16c 11 0
17a 15 0
17b 15 0
17c 12 0
18a 16 0
18b 14 0
18c 15 0
19a 11 0
19b 11 0
19c 15 0
2Qa 14 0
20b 15 0
20c 16 0
Refer Figure 4.3
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DISC DIFFUSION TEST (DDT) - S.pyogenes vs AMPICILLIN
Strain No. +veControl All potencies tested
(ampicillin) zone diam. mm
zone diam. mm
la 20 0
lb 25 0
lc 21 0
2a 24 0
2b 25 0
2c 20 0
3a 23 0
3b 20 0
3c 25 0
4a 24 0
4b 19 0
4c 20 0
sa 21 0
5b 26 0
5c 20 0
6a 19 0
6b 21 0
6c 24 0
7a 23 0
7b 25 0
7c 26 0
8a 19 0
8b 24 0
8c 23 0
9a 25 0
9b 20 0
9c 19 0
lOa 20 0
lOb 25 0
lOC 21 0
l1a 20 0
llb 19 0
llc 18 0
12a' 20 0
12b 23 0
12c 25 0
13a 22 0
13b 20 0
13c 19 0
14a 21 0
14b 25 0
14c 24 0
15a 20 0
15b 25 0
15c 26 0
16a 19 0
16b 17 0
16c 13 0
17a 25 0
17b 28 0
17c 25 0
18a 25 0
18b 20 0
18c 19 0
19a 23 0
19b 25 0
19c 23 0
20a 20 0
20b 21 0
20C 26 0
Refer Figure 4.4
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APPENDIX 8
Tube Potency Test data
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Tube Potency Test - C.albicans vs Echinacea products
Potencies mean std dey. std err. 95% conf 99% conf size total min max min. + missing other skewness
control 1.42e+5 1.93e+4 2495.11 4992.81 6641.86 60.00 8.4ge+6 1.01e+5 1.86e+5 1.01e+5 0.00 0.00 0.34
Ea MT 1.33e+5 1.93e+4 2495.11 4982.52 6628.17 60.00 8.QOe+6 8.03e+4 1.78e+5 8.03e+4 0.00 0.00 0.05
Ea 3CH 1.33e+5 3.05e+4 2489.97 7880.22 1.05e+4 60.00 8.QOe+6 2.2ge+4 2.12e+5 2.2ge+4 0.00 0.00 -0.37
Ea 9CH 1.43e+5 2.31e+4 3938.07 5975.58 7949.23 60.00 8.55e+6 6.0ge+4 1.84e+5 6.0ge+4 0.00 0.00 -1.30
Ea 15CH 1.42e+5 2.11e+4 2986.25 5445.95 7244.67 60.00 8.4ge+6 1.00e+4 2.11e+5 1.00e+5 0.00 0.00 0.30
EalEp MT 1.46e+5 1.7ge+4 2721.57 4628.63 6157.40 60.00 8.77e+6 1.11e+5 1.84e+5 1.11e+5 0.00 0.00 0.27
EaJEp 3CH 1.47e+5 2.41e+4 2313.12 6214.23 8266.70 60.00 8.82e+6 4.10e+4 1.84e+5 4.10e+4 0.00 0.00 -1.91
EalEp 9CH 1.52e+5 2.33e+4 3105.51 6021.59 8010.43 60.00 9.12e+6 1.02e+5 1.98e+5 1.02e+5 0.00 0.00 -0.22
EaJEp15CH 1.64e+5 2.04e+4 3009.24 5275.04 7017.31 60.00 9.86e+6 1.02e+5 2.05e+5 1.02e+5 0.00 0.00 -0.65
Ep MT 1.43e+5 2.37e+4 2636.16 6126.15 8149.52 60.00 8.56e+6 6.22e+4 1.87e+5 6022e+4 0.00 0.00 -0.71
Ep3CH 1.3ge+5 2.5Oe+4 3061.49 6457.15 8589.86 60.00 8.34e+6 6045.00 1.84e+5 6045.00 0.00 0.00 -2.37
Ep9CH 1.37e+5 2.12e+4 3226.97 5477.78 7287.01 60.00 8.25e+6 9.31e+4 1.84e+5 9.31e+4 0.00 0.00 -0.14
Ep 15CH 1.44e+5 1.9Oe+4 2737.48 4907.64 6528.57 60.00 8.67e+6 1.04e+5 1.84e+5 1.04e+5 0.00 0.00 0.10
ea mean 1.38e+5 4695.76 2100.01 5830.42 9666.12 5.00 6.92e+5 1.33e+5 1.43e+5 1.33e+5 0.00 0.00 -0.38
2.27e+4 4656.45 2082.43 5781.61 9585.19 5.00 1.13e+5 1.93e+4 3.05e+4 1.93e+4 0.00 0.00 1.11
easem 2926.20 601.14 268.84 74640 1237.44 5.00 1.46e+4 2489.97 3938.07 2489.97 0.00 0.00 1.11
00
Tube Potency Test - S.pyogenes vs Echinacea products
Potencies mean std dey. std err. 95% cant 99% cant size total min max min.+ missing other skewness
control 5.51e+6 3.93e+5 5.07e+4 1.01e+5 1.35e+5 60.00 3.31e+8 4.61e+6 7.08e+6 4061e+6 0.00 0.00 0.59
Ea MT 6.22e+6 4.98e+5 6.43e+4 1.29e+5 1.71e+5 60.00 3.73e+8 5.00e+6 7.18e+6 s.ooe-s 0.00 0.00 -0.24
Ea3CH 5.9Oe+6 5.81e+5 7.50e+4 1.50e+5 2.00e+5 60.00 3.54e+8 3.78e+6 7.13e+6 3.78e+6 0.00 0.00 -0.96
Ea9CH 5.83e+6 4.93e+5 6.36e+4 1.27e+5 1.69e+5 60.00 3.5Oe+8 4.99e+6 7.08e+6 4.9ge+6 0.00 0.00 0.20
Ea 15CH 5.82e+6 5.45e+5 7.04e+4 1.41e+5 1.87e+5 60.00 3.49e+8 4.26e+6 7.08e+6 4.26e+6 0.00 0.00 -0.23
EalEp MT 5.82e+6 3.46e+5 4.47e+4 8.95e+4 1.1ge+5· 60.00 3.49e+8 4.49e+6 7.08e+6 4.6ge+6 0.00 0.00 -0.16
EalEp 3CH 6.16e+6 3.38e+5 4.36e+4 8.72e+4 1.16e+5 60.00 3.70e+8 5.39e+6 7.08e+6 5.39e+6 0.00 0.00 0.28
EalEp9CH 6.14e+6 3.52e+5 4.55e+4 9.11e+4 1.21e+5 60.00 3.68e+8 5.28e+6 7.08e+6 5.28e+6 0.00 0.00 0.02
EalEp15CH 6.05e+6 3.61e+5 4.65e+4 9.31e+4 1.24e+5 60.00 3.63e+8 4.91e+6 7.08e+6 4.91e+6 0.00 0.00 -0.85
Ep MT 5.87e+6 3.54e+5 4.57e+4 9.14e+4 1.22e+5 60.00 3.52e+8 4.83e+6 7.08e+6 4.83e+6 0.00 0.00 -0.33
Ep3CH 5.67e+6 3.4ge+5 4.51e+4 9.02e+4 1.20e+5 60.00 3.4Oe+8 4.99e+6 7.08e+6 4.9ge+6 0.00 0.00 0.66
Ep9CH 5.66e+6 3.98e+5 5.02e+4 r.ooe-s 1.34e+5 60.00 3.40e+8 4.45e+6 7.08e+6 4.45e+6 0.00 0.00 -0.10
Ep15CH 5.24e+6 4.79e+5 6.19e+4 1.24e+5 1.65e+5 60.00 3.15e+8 4.33e+6 7.08e+6 4.33e+6 0.00 0.00 0.95
ea mean 5.5ge+6 2.33e+5 1.04e+5 2.90e+5 4.81e+5 5.00 2.80e+7 5.24e+6 5.87e+6 5.24e+6 0.00 0.00 -0.45
3.93e+5 5.23e+4 2.34e+4 6.49e+4 1.08e+5 5.00 1.96e+6 3.49e+5 4.79e+5 3.49e+5 0.00 0.00 0.99
ea sem 5.07e+4 6749.90 3018.65 8380.92 1.39e+4 5.00 2.54e+5 4.51e+4 6.19e+4 4.51e+4 0.00 0.00 0.99
KRUSKAL-WALLIS ONE WAY ANALYSIS OF VARIANCE • C.albicans vs Ea
Group N Missing
pc 60 0
EaMT 60 0
Ea3CH 60 0
Ea9CH 60 0
Ea15CH 60 0
Group Median 25% 75%
pc 137562.0 131419.5 153762.0
EaMT 134254.5 120417.0 143704.5
Ea3CH 131487.0 114747.0 151062.0
Ea9CH 144987.0 134187.0 155719.5
Ea 15CH 141544.5 131959.5 153222.0
H =13.4 with 4 degrees of freedom. (p =0.0093)
The differences in the median values among the treatment groups are greater
than would be expected by chance; there is a statistically significant difference
(p =0.00935).
To isolate the group or groups, that differ from the others use a multiple
comparison procedure.
Comparison of all Groups vs Control Group (Dunn's Method) :
Comparison Diff. of Ranks P Q
Ea MTvs pc 31.16 5 1.967
Ea 3CH vs oc 26.82 4 1.693
Ea 9CH vs pc 16.50 3 1.042
Ea 15CH vs pc 3.43 2 0.217
Comparison p<0.05
Ea MTvs pc No
Ea 3CH vs pc do not test
Ea 9CH vs pc do not test
Ea 15CH vs pc do not test
Refer Figure 4.5
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KRUSKAL-WALLIS ONE WAY ANALYSIS OF VARIANCE - C.albicans vs Ep
Group N Missing
pc 60 0
EpMT 60 0
Ep3CH 60 0
Ep9CH 60 0
Ep15CH 60 0
Group Median 25% 75%
pc 137562.0 131419.5 153762.0
EpMT 145999.0 131487.0 157542.0
Ep3CH 150927.0 142219.5 161052.0
Ep9CH 153829.5 142557.0 165777.0
Ep15CH 166452.0 152007.0 178602.0
H =42.3 with 4 degrees of freedom. (p =0.0001)
The differences in the median values among the treatment groups are greater
than would be expected by chance; there is a statistically significant difference
(p =0.0000000144).
To isolate the group or groups, that differ from the others use a multiple
comparison procedure.
Comparison of all Groups vs Control Group (Dunn's Method) :
Comparison Diff. of Ranks P Q
Ep 15CH vs pc 96.2 5 6.07
Ep 9CH vs pc 47.1 4 2.97
Ep 3CH vs pc 34.6 3 2.19
Ep MTvs pc 18.2 2 1.15
<0.05
Yes
Yes
No
do not test
Refer Figure 4.6
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KRUSKAL-WALLIS ONE WAY ANALYSIS OF VARIANCE - C.albicans vs Ea/Ep
Group N Missina
pc 60 0
Ea/EP MT 60 0
Ea/Ep 3CH 60 0
Ea/Ep 9CH 60 0
Ea/Ep 15CH 60 0
Group Median 25% 75%
pc 137562.0 131419.5 153762.0
Ea/Ep MT 143097.0 130812.0 155854.5
Ea/Ep 3CH 138507.0 130407.0 151467.0
Ea/Ep 9CH 139452.0 126424.5 151804.5
Ea/Ep 15CH 143434.5 129462.0 159297.0
H = 3.39 with 4 degrees of freedom. (p = 0.4944)
The difference in the median values among the treatment groups are not great
enough to exclude the possibility that the difference is due to random sampling
variability; there is not a statistically significant difference (p =0.494).
Refer Figure 4.7
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KRUSKAL-WALLIS ONE WAY ANALYSIS OF VARIANCE· S.pyogenes vs EB
Group N Missing
pc 60 0
EaMT 60 0
Ea3CH 60 0
Ea9CH 60 0
Ea15CH 60 0
Group Median 25% 75%
pc 5545886.5 5300635.0 5719162.0
EaMT 5912430.5 5773810.0 6032390.0
Ea3CH 5733823.5 553922.0 5808465.0
Ea9CH 5731158.0 5469912.0 5899102.0
Ea 15CH 5245986.5 4976743.0 5477909.0
H =82.2 with 4 degrees of freedom. (p =0.0001)
The differences in the median values among the treatment groups are greater
than would be expected by chance; there is a statistically significant difference
(p =6.1OE-017).
To isolate the group or groups, that differ from the others use a multiple
comparison procedure.
Comparison of all Groups vs Control Group (Dunn's Method) :
Comparison Ditt. of Ranks P Q
Ea MTvs pc 87.9 5 5.55
Ea 15CH vs pc 49.1 4 3.10
Ea 9CH vs oc 38.2 3 2.41
Ea 3CH vs pc 34.7 2 2.19
Comparison p<0.05
Ea MT vs pc Yes
Ea 15CH vs oc Yes
Ea 9CH vs pc No
Ea 3CH vs oc do not test
Refer Figure 4.8
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KRUSKAL-WALLIS ONE WAY ANALYSIS OF VARIANCE - S.pyogenes vs Ep
Group N Missing
pc 60 0
EpMT 60 0
Ep3CH 60 0
Ep9CH 60 0
Ep15CH 60 0
Group Median 25% 75%
pc 5545886.5 5300653.0 5719162.0
EpMT 6234989.0 5925759.0 6485572.5
Ep3CH 6005733.0 5635190.0 6192337.0
Ep9CH 5816462.5 5525893.5 6147019.0
Ep15CH 5915096.0 5579209.0 6109698.0
H =61.1 with 4 degrees of freedom. (p =<0.0001)
The differences in the median values among the treatment groups are greater
than would be expected by chance; there is a statistically significant difference
(p =1.71E-Q12).
To isolate the group or groups, that differ from the others use a multiple
comparison procedure.
Comparison of all Groups vs Control Group (Dunn's Method) :
Comparison Diff. of Ranks P Q
Ep MT vs pc 121.8 5 7.69
Ep 3CH vs pc 76.3 4 4.82
Ep 15CH vs oc 58.0 3 3.66
Ep 9CH vs pc 56.8 2 3.59
<0.05
Yes
Yes
Yes
Yes
Refer Figure 4.9
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KRUSKAL-WALLIS ONEWAY ANALYSIS OF VARIANCE - S.pyogenes vs Ea/Ep
Group N Missing
pc 60 0
Ea/Ep MT 60 0
Ea/Ep 3CH 60 0
Ea/Ep 9CH 60 0
Ea/Ep 15CH 60 0
Group Median 25% 75%
pc 5545886.5 5300635.0 5719162.0
Ea/Ep MT 5832457.5 5659182.0 5992404.0
Ea/Ep 3CH 6152350.5 5888438.5 6378941.0
EalEp9CH 6117695.5 5944420.0 6352283.5
Ea/Ep 15CH 6088371.5 5912430.5 6274310.0
H = 108.9 with 4 degrees of freedom. (p =<0.0001)
The difference in the median values among the treatment groups are greater than
would be expected by chance; there is a statistically significant difference
(p =1.24E-022).
To isolate the group or groups, that differ from the others use a multiple
comparison procedure.
Comparison of all Groups vs Control Group (Dunn's Method) :
Comparison Diff. of Ranks P Q
Ea/Ep 3CH vs pc 135.5 5 8.36
Ea/Ep 9CH vs pc 131.2 4 8.28
Ea/Ep 15CH vs pc 118.6 3 7.49
Ea/Ep MT vs pc 58.7 2 3.70
<0.05
Yes
Yes
Yes
Yes
Refer Figure 4.10
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